```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5925 Engrossed in House (EH)]

<DOC>
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
115th CONGRESS
  2d Session
                                H. R. 5925

_______________________________________________________________________

                                 AN ACT

 
 To codify provisions relating to the Office of National Drug Control, 
                        and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Coordinated Response through 
Interagency Strategy and Information Sharing Act'' or the ``CRISIS 
Act''.

SEC. 2. OFFICE OF NATIONAL DRUG CONTROL.

    (a) Redesignation.--The Office of National Drug Control Policy 
shall be known as the ``Office of National Drug Control''.
    (b) References.--Any reference in any other Federal law, Executive 
order, rule, regulation, or delegation of authority, or any document of 
or relating to the Office of National Drug Control Policy is deemed to 
refer to the Office of National Drug Control.
    (c) Codification.--Subtitle I of title 31, United States Code, is 
amended by adding at the end the following new chapter:

             ``CHAPTER 10--OFFICE OF NATIONAL DRUG CONTROL

                         ``subchapter i--office

``1001. Definitions.
``1002. Office of National Drug Control.
``1003. Administration of the Office.
``1004. National drug control program budget.
``1005. National drug control strategy.
``1006. Development of an annual national drug control assessment.
``1007. Monitoring and evaluation of national drug control program.
``1008. Coordination and oversight of the national drug control 
                            program.
``1009. Emerging threats task force, plan, campaign.
``1010. National and international coordination.
``1011. Interdiction.
``1012. Treatment coordinator.
``1013. Critical information coordination.
``1014. Authorization of appropriations.
         ``subchapter ii--drug-free communities support program

``1021. Establishment of drug-free communities support program.
``1022. Program authorization.
``1023. Information collection and dissemination with respect to grant 
                            recipients.
``1024. Technical assistance and training.
``1025. Supplemental grants for coalition mentoring activities.
``1026. Authorization for National Community Antidrug Coalition 
                            Institute.
``1027. Definitions.
``1028. Drug-free communities reauthorization.

                         ``SUBCHAPTER I--OFFICE

``Sec. 1001. Definitions
    ``In this chapter:
            ``(1) Agency.--The term `agency' has the meaning given the 
        term `executive agency' in section 102.
            ``(2) Appropriate congressional committees.--
                    ``(A) In general.--The term `appropriate 
                congressional committees' means--
                            ``(i) the Committee on the Judiciary, the 
                        Committee on Appropriations, the Committee on 
                        Health, Education, Labor, and Pensions, and the 
                        Caucus on International Narcotics Control of 
                        the Senate; and
                            ``(ii) the Committee on Oversight and 
                        Government Reform, the Committee on the 
                        Judiciary, the Committee on Energy and 
                        Commerce, and the Committee on Appropriations 
                        of the House of Representatives.
                    ``(B) Submission to congress.--Any submission to 
                Congress shall mean submission to the appropriate 
                congressional committees.
            ``(3) Demand reduction.--The term `demand reduction' means 
        any activity conducted by a National Drug Control Program 
        Agency, other than an enforcement activity, that is intended to 
        reduce or prevent the use of drugs or support or provide 
        treatment and recovery efforts, including--
                    ``(A) education about the dangers of illicit drug 
                use;
                    ``(B) services, programs, or strategies to prevent 
                substance use disorder, including evidence-based 
                education campaigns, community-based prevention 
                programs, collection and disposal of unused 
                prescription drugs, and services to at-risk populations 
                to prevent or delay initial use of an illicit drug;
                    ``(C) substance use disorder treatment;
                    ``(D) illicit drug use research;
                    ``(E) drug-free workplace programs;
                    ``(F) drug testing, including the testing of 
                employees;
                    ``(G) interventions for illicit drug use and 
                dependence;
                    ``(H) expanding availability of access to health 
                care services for the treatment of substance use 
                disorders;
                    ``(I) international drug control coordination and 
                cooperation with respect to activities described in 
                this paragraph;
                    ``(J) pre- and post-arrest criminal justice 
                interventions such as diversion programs, drug courts, 
                and the provision of evidence-based treatment to 
                individuals with substance use disorders who are 
                arrested or under some form of criminal justice 
                supervision, including medication assisted treatment;
                    ``(K) other coordinated and joint initiatives among 
                Federal, State, local, and Tribal agencies to promote 
                comprehensive drug control strategies designed to 
                reduce the demand for, and the availability of, illegal 
                drugs;
                    ``(L) international illicit drug use education, 
                prevention, treatment, recovery, research, 
                rehabilitation activities, and interventions for 
                illicit drug use and dependence; and
                    ``(M) research related to any of the activities 
                described in this paragraph.
            ``(4) Director.--The term `Director' means the Director of 
        the Office of National Drug Control.
            ``(5) Drug.--The term `drug' has the meaning given the term 
        `controlled substance' in section 102(6) of the Controlled 
        Substances Act (21 U.S.C. 802(6)).
            ``(6) Drug control.--The term `drug control' means any 
        activity conducted by a National Drug Control Program Agency 
        involving supply reduction or demand reduction.
            ``(7) Emerging drug threat.--The term `emerging drug 
        threat' means the occurrence of a new and growing trend in the 
        use of an illicit drug or class of drugs, including rapid 
        expansion in the supply of or demand for such drug.
            ``(8) Illicit drug use; illicit drugs; illegal drugs.--The 
        terms `illicit drug use', `illicit drugs', and `illegal drugs' 
        include the illegal or illicit use of prescription drugs.
            ``(9) Law enforcement.--The term `law enforcement' or `drug 
        law enforcement' means all efforts by a Federal, State, local, 
        or Tribal government agency to enforce the drug laws of the 
        United States or any State, including investigation, arrest, 
        prosecution, and incarceration or other punishments or 
        penalties.
            ``(10) National drug control program.--The term `National 
        Drug Control Program' means programs, policies, and activities 
        undertaken by National Drug Control Program Agencies pursuant 
        to the responsibilities of such agencies under the National 
        Drug Control Strategy, including any activities involving 
        supply reduction, demand reduction, or State, local, and Tribal 
        affairs.
            ``(11) National drug control program agency.--The term 
        `National Drug Control Program Agency' means any agency (or 
        bureau, office, independent agency, board, division, 
        commission, subdivision, unit, or other component thereof) that 
        is responsible for implementing any aspect of the National Drug 
        Control Strategy, including any agency that receives Federal 
        funds to implement any aspect of the National Drug Control 
        Strategy, but does not include any agency that receives funds 
        for drug control activity solely under the National 
        Intelligence Program or the Military Intelligence Program.
            ``(12) National drug control strategy; strategy.--The term 
        `National Drug Control Strategy' or `Strategy' means the 
        strategy developed and submitted to Congress under section 
        1005.
            ``(13) Nonprofit organization.--The term `nonprofit 
        organization' means an organization that is described in 
        section 501(c)(3) of the Internal Revenue Code of 1986 and 
        exempt from tax under section 501(a) of such Code.
            ``(14) Office.--The term `Office' means the Office of 
        National Drug Control.
            ``(15) State, local, and tribal affairs.--The term `State, 
        local, and Tribal affairs' means domestic activities conducted 
        by a National Drug Control Program Agency that are intended to 
        reduce the availability and use of illegal drugs, including--
                    ``(A) coordination and enhancement of Federal, 
                State, local, and Tribal law enforcement drug control 
                efforts;
                    ``(B) coordination and enhancement of efforts among 
                National Drug Control Program Agencies and State, 
                local, and Tribal demand reduction and supply reduction 
                agencies;
                    ``(C) coordination and enhancement of Federal, 
                State, local, and Tribal law enforcement initiatives to 
                gather, analyze, and disseminate information and law 
                enforcement intelligence relating to drug control among 
                domestic law enforcement agencies; and
                    ``(D) other coordinated and joint initiatives among 
                Federal, State, local, and Tribal agencies to promote 
                comprehensive drug control strategies designed to 
                reduce the demand for, and the availability of, illegal 
                drugs.
            ``(16) Substance use disorder treatment.--The term 
        `substance use disorder treatment' means an evidence-based, 
        professionally directed, deliberate, and planned regimen 
        including evaluation, observation, medical monitoring, and 
        rehabilitative services and interventions such as 
        pharmacotherapy, behavioral therapy, and individual and group 
        counseling, on an inpatient or outpatient basis, to help 
        patients with substance use disorder reach recovery.
            ``(17) Supply reduction.--The term `supply reduction' means 
        any activity or program conducted by a National Drug Control 
        Program Agency that is intended to reduce the availability or 
        use of illegal drugs in the United States or abroad, 
        including--
                    ``(A) law enforcement outside the United States;
                    ``(B) domestic law enforcement;
                    ``(C) source country programs, including economic 
                development programs primarily intended to reduce the 
                production or trafficking of illicit drugs;
                    ``(D) activities to control international 
                trafficking in, and availability of, illegal drugs, 
                including--
                            ``(i) accurate assessment and monitoring of 
                        international drug production and interdiction 
                        programs and policies; and
                            ``(ii) coordination and promotion of 
                        compliance with international treaties relating 
                        to the production, transportation, or 
                        interdiction of illegal drugs;
                    ``(E) activities to conduct and promote 
                international law enforcement programs and policies to 
                reduce the supply of drugs;
                    ``(F) activities to facilitate and enhance the 
                sharing of domestic and foreign intelligence 
                information among National Drug Control Program 
                Agencies, relating to the production and trafficking of 
                drugs in the United States and in foreign countries;
                    ``(G) activities to prevent the diversion of drugs 
                for their illicit use; and
                    ``(H) research related to any of the activities 
                described in this paragraph.
``Sec. 1002. Office of National Drug Control
    ``(a) Establishment of Office.--There is established in the 
Executive Office of the President an Office of National Drug Control, 
which shall--
            ``(1) lead the national drug control effort, including 
        coordinating with Nation Drug Control Program Agencies;
            ``(2) coordinate and oversee the implementation of the 
        national drug control policy, including the National Drug 
        Control Strategy;
            ``(3) assess and certify the adequacy of National Drug 
        Control Programs and the budget for those programs;
            ``(4) monitor and evaluate the effectiveness of national 
        drug control policy efforts, including the National Drug 
        Control Program Agencies' programs, by developing and applying 
        specific goals and performance measurements and tracking 
        program-level spending;
            ``(5) identify and respond to emerging drug threats related 
        to illicit drug use;
            ``(6) administer and evaluate grant programs in furtherance 
        of the National Drug Control Strategy; and
            ``(7) facilitate broad-scale information sharing and data 
        standardization among Federal, State, and local entities to 
        support the national drug control efforts.
    ``(b) Director of National Drug Control and Deputy Director.--
            ``(1) Director.--
                    ``(A) In general.--There shall be at the head of 
                the Office a Director who shall hold the same rank and 
                status as the head of an executive department listed in 
                section 101 of title 5.
                    ``(B) Appointment.--The Director shall be appointed 
                by the President, by and with the advice and consent of 
                the Senate, and shall serve at the pleasure of the 
                President.
            ``(2) Deputy director.--
                    ``(A) In general.--There shall be a Deputy Director 
                who shall report directly to the Director, be appointed 
                by the President, and serve at the pleasure of the 
                President.
                    ``(B) Responsibilities.--The Deputy Director 
                shall--
                            ``(i) carry out the responsibilities 
                        delegated by the Director; and
                            ``(ii) be responsible for effectively 
                        coordinating with the each Coordinator 
                        established under this chapter.
    ``(c) Responsibilities.--
            ``(1) Policies, goals, objectives, and priorities.--The 
        Director shall assist the President in directing national drug 
        control efforts, including establishing policies, goals, 
        objectives, and priorities for the National Drug Control 
        Program that are based on evidence-based research.
            ``(2) Consultation.--To formulate the National Drug Control 
        policies, goals, objectives, and priorities, the Director--
                    ``(A) shall consult with--
                            ``(i) State and local governments;
                            ``(ii) National Drug Control Program 
                        Agencies;
                            ``(iii) each committee, working group, 
                        council, or other entity established under this 
                        chapter, as appropriate;
                            ``(iv) the public;
                            ``(v) appropriate congressional committees; 
                        and
                            ``(vi) any other person in the discretion 
                        of the Director; and
                    ``(B) may--
                            ``(i) establish advisory councils;
                            ``(ii) acquire data from agencies; and
                            ``(iii) request data from any other entity.
``Sec. 1003. Administration of the Office
    ``(a) Employment.--
            ``(1) Authority of the director.--The Director may select, 
        appoint, employ, and fix compensation of such officers and 
        employees of the Office as may be necessary to carry out the 
        functions of the Office under this chapter.
            ``(2) Prohibitions.--
                    ``(A) Generally.--No person shall serve as Director 
                or Deputy Director while serving in any other position 
                in the Federal Government.
                    ``(B) Prohibition on political campaigning.--Any 
                officer or employee of the Office who is appointed to 
                that position by the President, by and with the advice 
                and consent of the Senate, may not participate in 
                Federal election campaign activities, except that such 
                officer or employee is not prohibited by this 
                subparagraph from making contributions to individual 
                candidates.
    ``(b) Prohibition on the Use of Funds for Political Campaigns or 
Ballot Initiatives.--No funds authorized under this chapter may be 
obligated for the purpose of influencing any Federal, State, or local 
election or ballot initiative.
    ``(c) Personnel Detailed to Office.--
            ``(1) Evaluations.--Notwithstanding any provision of 
        chapter 43 of title 5, the Director shall perform the 
        evaluation of the performance of any employee detailed to the 
        Office for purposes of the applicable performance appraisal 
        system established under such chapter for any rating period, or 
        part thereof, that such employee is detailed to the Office.
            ``(2) Compensation.--
                    ``(A) Bonus payments.--Subject to the availability 
                of appropriations, the Director may provide periodic 
                bonus payments to any employee detailed to the Office.
                    ``(B) Restrictions.--An amount paid under this 
                paragraph to an employee for any period--
                            ``(i) shall not be greater than 20 percent 
                        of the basic pay paid or payable to such 
                        employee for such period; and
                            ``(ii) shall be in addition to the basic 
                        pay of such employee.
                    ``(C) Aggregate amount.--The aggregate amount paid 
                during any fiscal year to an employee detailed to the 
                Office as basic pay, awards, bonuses, and other 
                compensation shall not exceed the annual rate payable 
                at the end of such fiscal year for positions at level 
                III of the Executive Schedule.
    ``(d) Congressional Access to Information.--The location of the 
Office in the Executive Office of the President shall not be construed 
as affecting access by Congress, or any committee of the House of 
Representatives or the Senate, to any--
            ``(1) information, document, or study in the possession of, 
        or conducted by or at the direction of the Director; or
            ``(2) personnel of the Office.
    ``(e) Other Authorities of the Director.--In carrying out this 
chapter, the Director may--
            ``(1) use for administrative purposes, on a reimbursable 
        basis, the available services, equipment, personnel, and 
        facilities of Federal, State, and local agencies;
            ``(2) procure the services of experts and consultants in 
        accordance with section 3109 of title 5 relating to 
        appointments in the Federal Service, at rates of compensation 
        for individuals not to exceed the daily equivalent of the rate 
        of pay payable under level IV of the Executive Schedule under 
        section 5311 of such title; and
            ``(3) use the mails in the same manner as any other agency.
    ``(f) General Services Administration.--The Administrator of 
General Services shall provide to the Director, on a reimbursable 
basis, such administrative support services as the Director may 
request.
``Sec. 1004. National drug control program budget
    ``(a) Budget Recommendations.--Not later than July 1 of each year, 
the Director shall provide to the head of each National Drug Control 
Program Agency budget recommendations, including requests for specific 
initiatives that are consistent with the priorities of the President 
under the National Drug Control Strategy, which shall--
            ``(1) apply to the budget for the next fiscal year 
        scheduled for formulation under chapter 11, and each of the 4 
        subsequent fiscal years; and
            ``(2) address funding priorities developed in the National 
        Drug Control Strategy.
    ``(b) Responsibilities of National Drug Control Program Agencies.--
            ``(1) In general.--For each fiscal year, the head of each 
        National Drug Control Program Agency shall transmit to the 
        Director a copy of the proposed drug control budget request of 
        such agency at the same time as that budget request is 
        submitted to their superiors (and before submission to the 
        Office of Management and Budget) in the preparation of the 
        budget of the President submitted to Congress under section 
        1105(a).
            ``(2) Submission of drug control budget requests.--The head 
        of each National Drug Control Program Agency shall ensure 
        timely development and submission to the Director of each 
        proposed drug control budget request transmitted pursuant to 
        this subsection, in such format as may be designated by the 
        Director with the concurrence of the Director of the Office of 
        Management and Budget.
            ``(3) Content of drug control budget requests.--A drug 
        control budget request submitted by the head of a National Drug 
        Control Program Agency under this subsection shall include all 
        requests for funds for any drug control activity undertaken by 
        such agency, including demand reduction, supply reduction, and 
        State, local, and Tribal affairs, including any drug law 
        enforcement activities. If an activity has both drug control 
        and nondrug control purposes or applications, such agency shall 
        estimate by a documented calculation the total funds requested 
        for that activity that would be used for drug control, and 
        shall set forth in its request the basis and method for making 
        the estimate.
    ``(c) Review and Certification of Budget Requests and Budget 
Submissions of National Drug Control Program Agencies.--
            ``(1) In general.--The Director shall review each drug 
        control budget request submitted to the Director under 
        subsection (b).
            ``(2) Review of budget requests.--
                    ``(A) Inadequate requests.--If the Director 
                concludes that a budget request submitted under 
                subsection (b) is inadequate, in whole or in part, to 
                implement the objectives of the National Drug Control 
                Strategy with respect to the agency or program at issue 
                for the year for which the request is submitted, the 
                Director shall submit to the head of the applicable 
                National Drug Control Program Agency a written 
                description identifying the funding levels and specific 
                initiatives that would, in the determination of the 
                Director, make the request adequate to implement those 
                objectives.
                    ``(B) Adequate requests.--If the Director concludes 
                that a budget request submitted under subsection (b) is 
                adequate to implement the objectives of the National 
                Drug Control Strategy with respect to the agency or 
                program at issue for the year for which the request is 
                submitted, the Director shall submit to the head of the 
                applicable National Drug Control Program Agency a 
                written statement confirming the adequacy of the 
                request.
                    ``(C) Record.--The Director shall maintain a record 
                of each description submitted under subparagraph (A) 
                and each statement submitted under subparagraph (B).
            ``(3) Specific requests.--The Director shall not confirm 
        the adequacy of any budget request that requests a level of 
        funding that will not enable achievement of the goals of the 
        National Drug Control Strategy, including--
                    ``(A) requests funding for Federal law enforcement 
                activities that do not adequately compensate for 
                transfers of drug enforcement resources and personnel 
                to law enforcement and investigation activities;
                    ``(B) requests funding for law enforcement 
                activities on the borders of the United States that do 
                not adequately direct resources to drug interdiction 
                and enforcement;
                    ``(C) requests funding for substance use disorder 
                treatment activities that do not provide adequate 
                results and accountability measures;
                    ``(D) requests funding for substance use disorder 
                treatment activities that do not adequately support and 
                enhance Federal substance use disorder programs and 
                capacity; and
                    ``(E) requests funding for the operations and 
                management of the Department of Homeland Security that 
                does not include a specific request for funds for the 
                Office of Counternarcotics Enforcement to carry out its 
                responsibilities under section 878 of the Homeland 
                Security Act of 2002 (6 U.S.C. 458).
            ``(4) Agency response.--
                    ``(A) In general.--The head of a National Drug 
                Control Program Agency that receives a description 
                under paragraph (2)(A) shall include the funding levels 
                and initiatives described by the Director in the budget 
                submission for that agency to the Office of Management 
                and Budget.
                    ``(B) Impact statement.--The head of a National 
                Drug Control Program Agency that has altered its budget 
                submission under this paragraph shall include as an 
                appendix to the budget submission for that agency to 
                the Office of Management and Budget an impact statement 
                that summarizes--
                            ``(i) the changes made to the budget under 
                        this paragraph; and
                            ``(ii) the impact of those changes on the 
                        ability of that agency to perform its other 
                        responsibilities, including any impact on 
                        specific missions or programs of the agency.
                    ``(C) Congressional notification.--The head of a 
                National Drug Control Program Agency shall submit a 
                copy of any impact statement under subparagraph (B) to 
                the Senate, the House of Representatives, and the 
                appropriate congressional committees, at the time the 
                budget for that agency is submitted to Congress under 
                section 1105(a).
            ``(5) Certification of budget submissions.--
                    ``(A) In general.--At the time the head of a 
                National Drug Control Program Agency submits its budget 
                request to the Office of Management and Budget, the 
                head of the National Drug Control Program Agency shall 
                submit a copy of the budget request to the Director.
                    ``(B) Review and certification of submissions.--The 
                Director shall review each budget submission submitted 
                under subparagraph (A) and submit to the appropriate 
                congressional committees one of the following:
                            ``(i) A written certification of the budget 
                        submission for the agency indicating such 
                        request fully funds the National Drug Control 
                        Programs as necessary to achieve the goals of 
                        the National Drug Control Strategy, including a 
                        written statement explaining the basis for the 
                        determination that the budget submission 
                        provides sufficient resources for the agency to 
                        achieve the goals of the Strategy.
                            ``(ii) A written certification of the 
                        budget submission for the agency indicating 
                        such request partially funds the National Drug 
                        Control Programs as necessary to achieve the 
                        goals of the Strategy, including a written 
                        statement explaining the basis for the 
                        determination to certify the budget submission 
                        and identifying the level of funding sufficient 
                        to achieve the goals of the Strategy.
                            ``(iii) A written decertification of the 
                        budget submission for the agency indicating the 
                        Director is unable to determine whether such 
                        budget submission for the agency fully funds or 
                        partially funds the National Drug Control 
                        Programs as necessary to achieve the goals of 
                        the National Drug Control Strategy, including a 
                        written statement identifying the additional 
                        information necessary for the Director to make 
                        a determination on such budget submission and 
                        the level of funding sufficient to achieve the 
                        goals of the Strategy.
                            ``(iv) A written decertification of the 
                        budget submission for the agency indicating 
                        that such budget is insufficient to fund the 
                        National Drug Control Programs as necessary to 
                        achieve the goals of the Strategy, including a 
                        written statement explaining the basis for the 
                        determination that the budget is insufficient 
                        and identifying the level of funding sufficient 
                        to achieve the goals of the Strategy.
    ``(d) National Drug Control Program Budget Proposal.--For each 
fiscal year, following the transmission of proposed drug control budget 
requests to the Director under subsection (b), the Director shall, in 
consultation with the head of each National Drug Control Program Agency 
and the head of each major national organization that represents law 
enforcement officers, agencies, or associations--
            ``(1) develop a consolidated National Drug Control Program 
        budget proposal designed to implement the National Drug Control 
        Strategy and to inform Congress and the public about the total 
        amount proposed to be spent on all supply reduction, demand 
        reduction, State, local, and Tribal affairs, including any drug 
        law enforcement, and other drug control activities by the 
        Federal Government, which shall conform to the content 
        requirements set forth in subsection (b)(3) and include--
                    ``(A) for each National Drug Control Program 
                Agency, a list of whether the funding level is full, 
                partial, or insufficient to achieve the goals of the 
                National Drug Control Strategy or whether the Director 
                is unable to make such determination;
                    ``(B) a statement describing the extent to which 
                any budget of a National Drug Control Program Agency 
                with less than full funding hinders progress on 
                achieving the goals of the National Drug Control 
                Strategy; and
                    ``(C) alternative funding structures that could 
                improve progress on achieving the goals of the National 
                Drug Control Strategy; and
            ``(2) submit the consolidated budget proposal to the 
        President and Congress.
    ``(e) Budget Estimate or Request Submission to Congress.--Whenever 
the Director submits any budget estimate or request to the President or 
the Office of Management and Budget, the Director shall concurrently 
transmit to the appropriate congressional committees a detailed 
statement of the budgetary needs of the Office to execute its mission 
based on the good-faith assessment of the Director.
    ``(f) Reprogramming and Transfer Requests.--
            ``(1) In general.--No National Drug Control Program Agency 
        shall submit to Congress a reprogramming or transfer request 
        with respect to any amount of appropriated funds in an amount 
        exceeding $1 million that is included in the National Drug 
        Control Program budget unless the request has been approved by 
        the Director. If the Director has not responded to a request 
        for reprogramming subject to this paragraph within 30 days 
        after receiving notice of the request having been made, the 
        request shall be deemed approved by the Director under this 
        paragraph and forwarded to Congress.
            ``(2) Appeal.--The head of any National Drug Control 
        Program Agency may appeal to the President any disapproval by 
        the Director of a reprogramming or transfer request under this 
        subsection.
``Sec. 1005. National drug control strategy
    ``(a) In General.--
            ``(1) Statement of drug policy priorities.--The Director 
        shall release a statement of drug control policy priorities in 
        the calendar year of a Presidential inauguration following the 
        inauguration but not later than April 1.
            ``(2) National drug control strategy submitted by the 
        president.--Not later than the first Monday in February 
        following the year in which the term of the President 
        commences, the President shall submit to Congress a National 
        Drug Control Strategy.
    ``(b) Development of the National Drug Control Strategy.--
            ``(1) Promulgation.--The Director shall promulgate the 
        National Drug Control Strategy, which shall set forth a 
        comprehensive plan to reduce illicit drug use and the 
        consequences of such illicit drug use in the United States by 
        limiting the availability of and reducing the demand for 
        illegal drugs and promoting prevention, early intervention, 
        treatment, and recovery support for individuals with substance 
        use disorders.
            ``(2) State and local commitment.--The Director shall seek 
        the support and commitment of State, local, and Tribal 
        officials in the formulation and implementation of the National 
        Drug Control Strategy.
            ``(3) Strategy based on evidence.--The Director shall 
        ensure the National Drug Control Strategy is based on the best 
        available medical and scientific evidence regarding the 
        policies that are most effective in reducing the demand for and 
        supply of illegal drugs.
            ``(4) Process for development and submission of national 
        drug control strategy.--In developing and effectively 
        implementing the National Drug Control Strategy, the Director--
                    ``(A) shall consult with--
                            ``(i) the heads of the National Drug 
                        Control Program Agencies;
                            ``(ii) each Coordinator established under 
                        this chapter;
                            ``(iii) the Interdiction Committee, the 
                        Treatment Committee, and the Emerging Threats 
                        Task Force;
                            ``(iv) the appropriate congressional 
                        committees and any other committee of 
                        jurisdiction;
                            ``(v) State, local, and Tribal officials;
                            ``(vi) private citizens and organizations, 
                        including community and faith-based 
                        organizations, with experience and expertise in 
                        demand reduction;
                            ``(vii) private citizens and organizations 
                        with experience and expertise in supply 
                        reduction; and
                            ``(viii) appropriate representatives of 
                        foreign governments; and
                    ``(B) in satisfying the requirements of 
                subparagraph (A), shall ensure, to the maximum extent 
                possible, that State, local, and Tribal officials and 
                relevant private organizations commit to support and 
                take steps to achieve the goals and objectives of the 
                National Drug Control Strategy.
    ``(c) Contents of the National Drug Control Strategy.--
            ``(1) In general.--The National Drug Control Strategy 
        submitted under subsection (a)(2) shall include the following:
                    ``(A) A description of the current prevalence of 
                illicit drug use in the United States, including both 
                the availability of illicit drugs and the prevalence of 
                substance use disorders, which shall include the 
                following:
                            ``(i) Such description for the previous 3 
                        years for any drug identified as an emerging 
                        threat under section 1009 and any other illicit 
                        drug identified by the Director as having a 
                        significant impact on the prevalence of illicit 
                        drug use.
                            ``(ii) A summary of the data and trends 
                        presented in the Drug Control Data Dashboard 
                        required under section 1013.
                    ``(B) A mission statement detailing the major 
                functions of the National Drug Control Program.
                    ``(C) A list of comprehensive, research-based, 
                long-range, quantifiable goals for reducing illicit 
                drug use, including--
                            ``(i) the percentage of the total flow of 
                        illicit drugs to be interdicted during the time 
                        period covered by the Strategy; and
                            ``(ii) the number of individuals to receive 
                        substance use disorder treatment.
                    ``(D) A description of how each goal established 
                under subparagraph (C) will be achieved, including for 
                each goal--
                            ``(i) a list of each relevant National Drug 
                        Control Program Agency and each such agency's 
                        related programs, activities, and available 
                        assets and the role of each such program, 
                        activity, and asset in achieving such goal;
                            ``(ii) a list of relevant stakeholders and 
                        each such stakeholder's role in achieving such 
                        goal;
                            ``(iii) an estimate of Federal funding and 
                        other resources needed to achieve such goal;
                            ``(iv) a list of each existing or new 
                        coordinating mechanism needed to achieve such 
                        goal; and
                            ``(v) a description of the Office's role in 
                        facilitating the achievement of such goal.
                    ``(E) For each year covered by the Strategy, a 
                performance evaluation plan for each goal established 
                under subparagraph (C) for each National Drug Control 
                Program Agency, including--
                            ``(i) specific performance measures for 
                        each National Drug Control Program Agency and 
                        each such agency's related programs and 
                        activities;
                            ``(ii) annual and, to the extent 
                        practicable, quarterly objectives and targets 
                        for each performance measure; and
                            ``(iii) an estimate of Federal funding and 
                        other resources needed to achieve each 
                        performance objective and target.
                    ``(F) A list identifying existing data sources or a 
                description of data collection needed to evaluate 
                performance, including a description of how the 
                Director will obtain such data.
                    ``(G) A list of any anticipated challenges to 
                achieving the National Drug Control Strategy goals and 
                planned actions to address such challenges.
                    ``(H) A description of how each goal established 
                under subparagraph (C) was determined, including--
                            ``(i) a description of each required 
                        consultation and a description of how such 
                        consultation was incorporated;
                            ``(ii) data, research, or other information 
                        used to inform the determination to establish 
                        the goal; and
                            ``(iii) for any goal established under 
                        subparagraph (C)(i), a statement of whether the 
                        goal will be adequate to disrupt drug 
                        trafficking organizations that supply the 
                        majority of foreign-sourced illicit drugs 
                        trafficked into the United States.
                    ``(I) A 5-year projection for program and budget 
                priorities.
                    ``(J) A review of international, State, local, and 
                private sector drug control activities to ensure that 
                the United States pursues coordinated and effective 
                drug control at all levels of government.
                    ``(K) Such statistical data and information as the 
                Director considers appropriate to demonstrate and 
                assess trends relating to illicit drug use, the effects 
                and consequences of illicit drug use (including the 
                effects on children), supply reduction, demand 
                reduction, drug-related law enforcement, and the 
                implementation of the National Drug Control Strategy.
            ``(2) Additional strategies.--
                    ``(A) In general.--The Director shall include in 
                the National Drug Control Strategy the additional 
                strategies described under this paragraph and shall 
                comply with the following:
                            ``(i) Provide a copy of the additional 
                        strategies to the appropriate congressional 
                        committees and to the Committee on Armed 
                        Services and the Committee on Homeland Security 
                        of the House of Representatives, and the 
                        Committee on Homeland Security and Governmental 
                        Affairs and the Committee on Armed Services of 
                        the Senate.
                            ``(ii) Issue the additional strategies in 
                        consultation with the head of each relevant 
                        National Drug Control Program Agency, any 
                        relevant official of a State, local, or Tribal 
                        government, and the government of other 
                        relevant countries.
                            ``(iii) Not change any existing agency 
                        authority or construe any strategy described 
                        under this paragraph to amend or modify any law 
                        governing interagency relationship but may 
                        include recommendations about changes to such 
                        authority or law.
                            ``(iv) Present separately from the rest of 
                        any strategy described under this paragraph any 
                        information classified under criteria 
                        established by an Executive order, or whose 
                        public disclosure, as determined by the 
                        Director or the head of any relevant National 
                        Drug Control Program Agency, would be 
                        detrimental to the law enforcement or national 
                        security activities of any Federal, State, 
                        local, or Tribal agency.
                    ``(B) Requirement for southwest border 
                counternarcotics.--
                            ``(i) Purposes.--The Southwest Border 
                        Counternarcotics Strategy shall--
                                    ``(I) set forth the Government's 
                                strategy for preventing the illegal 
                                trafficking of drugs across the 
                                international border between the United 
                                States and Mexico, including through 
                                ports of entry and between ports of 
                                entry on that border;
                                    ``(II) state the specific roles and 
                                responsibilities of the relevant 
                                National Drug Control Program Agencies 
                                for implementing that strategy; and
                                    ``(III) identify the specific 
                                resources required to enable the 
                                relevant National Drug Control Program 
                                Agencies to implement that strategy.
                            ``(ii) Specific content related to drug 
                        tunnels between the united states and mexico.--
                        The Southwest Border Counternarcotics Strategy 
                        shall include--
                                    ``(I) a strategy to end the 
                                construction and use of tunnels and 
                                subterranean passages that cross the 
                                international border between the United 
                                States and Mexico for the purpose of 
                                illegal trafficking of drugs across 
                                such border; and
                                    ``(II) recommendations for criminal 
                                penalties for persons who construct or 
                                use such a tunnel or subterranean 
                                passage for such a purpose.
                    ``(C) Requirement for northern border 
                counternarcotics strategy.--
                            ``(i) Purposes.--The Northern Border 
                        Counternarcotics Strategy shall--
                                    ``(I) set forth the strategy of the 
                                Federal Government for preventing the 
                                illegal trafficking of drugs across the 
                                international border between the United 
                                States and Canada, including through 
                                ports of entry and between ports of 
                                entry on the border;
                                    ``(II) state the specific roles and 
                                responsibilities of each relevant 
                                National Drug Control Program Agency 
                                for implementing the strategy;
                                    ``(III) identify the specific 
                                resources required to enable the 
                                relevant National Drug Control Program 
                                Agencies to implement the strategy;
                                    ``(IV) be designed to promote, and 
                                not hinder, legitimate trade and 
                                travel; and
                                    ``(V) reflect the unique nature of 
                                small communities along the 
                                international border between the United 
                                States and Canada, ongoing cooperation 
                                and coordination with Canadian law, 
                                enforcement authorities, and variations 
                                in the volumes of vehicles and 
                                pedestrians crossing through ports of 
                                entry along the international border 
                                between the United States and Canada.
                            ``(ii) Specific content related to cross-
                        border indian reservations.--The Northern 
                        Border Counternarcotics Strategy shall 
                        include--
                                    ``(I) a strategy to end the illegal 
                                trafficking of drugs to or through 
                                Indian reservations on or near the 
                                international border between the United 
                                States and Canada; and
                                    ``(II) recommendations for 
                                additional assistance, if any, needed 
                                by Tribal law enforcement agencies 
                                relating to the strategy, including an 
                                evaluation of Federal technical and 
                                financial assistance, infrastructure 
                                capacity building, and interoperability 
                                deficiencies.
            ``(3) Classified information.--Any contents of the National 
        Drug Control Strategy that involve information properly 
        classified under criteria established by an Executive order 
        shall be presented to Congress separately from the rest of the 
        National Drug Control Strategy.
            ``(4) Selection of data and information.--In selecting data 
        and information for inclusion in the Strategy, the Director 
        shall ensure--
                    ``(A) the inclusion of data and information that 
                will permit analysis of current trends against 
                previously compiled data and information where the 
                Director believes such analysis enhances long-term 
                assessment of the National Drug Control Strategy; and
                    ``(B) the inclusion of data and information to 
                permit a standardized and uniform assessment of the 
                effectiveness of drug treatment programs in the United 
                States.
    ``(d) Annual Performance Supplement.--Not later than the first 
Monday in February of each year following the year in which the 
National Drug Control Strategy is submitted pursuant to subsection 
(a)(2), the Director shall submit to the appropriate congressional 
committees a supplement to the Strategy that shall include--
            ``(1) annual and, to the extent practicable, quarterly 
        quantifiable and measurable objectives and specific targets to 
        accomplish long-term quantifiable goals specified in the 
        Strategy; and
            ``(2) for each year covered by the Strategy, a performance 
        evaluation plan for each goal listed in the Strategy for each 
        National Drug Control Program Agency, including--
                    ``(A) specific performance measures for each 
                National Drug Control Program Agency and each such 
                agency's related programs and activities;
                    ``(B) annual and, to the extent practicable, 
                quarterly objectives and targets for each performance 
                measure; and
                    ``(C) an estimate of Federal funding and other 
                resources needed to achieve each performance objective 
                and target.
    ``(e) Submission of Revised Strategy.--
            ``(1) In general.--The President may submit to Congress a 
        revised National Drug Control Strategy that meets the 
        requirements of this section--
                    ``(A) at any time, upon a determination of the 
                President, in consultation with the Director, that the 
                National Drug Control Strategy in effect is not 
                sufficiently effective; or
                    ``(B) if a new President or Director takes office.
            ``(2) No submission.--In each year the President does not 
        submit a National Drug Control Strategy or a revised National 
        Drug Control Strategy, the Director shall evaluate the efficacy 
        and appropriateness of the goals of the National Drug Control 
        Strategy and include a statement affirming the adequacy of the 
        goals in the performance supplement under subsection (d).
    ``(f) Failure of President to Submit National Drug Control 
Strategy.--If the President does not submit a National Drug Control 
Strategy to Congress in accordance with subsection (a)(2), not later 
than 5 days after the first Monday in February following the year in 
which the term of the President commences, the President shall send a 
notification to the appropriate congressional committees--
            ``(1) explaining why the Strategy was not submitted; and
            ``(2) specifying the date by which the Strategy will be 
        submitted.
``Sec. 1006. Development of an annual national drug control assessment
    ``(a) Timing.--Not later than the first Monday in February of each 
year, the Director shall submit to the President, Congress, and the 
appropriate congressional committees, a report assessing the progress 
of each National Drug Control Program Agency toward achieving each 
goal, objective, and target contained in the National Drug Control 
Strategy applicable to the prior fiscal year.
    ``(b) Process for Development of the Annual Assessment.--Not later 
than November 1 of each year, the head of each National Drug Control 
Program Agency shall submit, in accordance with guidance issued by the 
Director, to the Director an evaluation of progress by the agency with 
respect to the National Drug Control Strategy goals using the 
performance measures for the agency developed under this chapter, 
including progress with respect to--
            ``(1) success in achieving the goals of the National Drug 
        Control Strategy;
            ``(2) success in reducing domestic and foreign sources of 
        illegal drugs;
            ``(3) success in expanding access to and increasing the 
        effectiveness of substance use disorder treatment;
            ``(4) success in protecting the borders of the United 
        States (and in particular the Southwestern border of the United 
        States) from penetration by illegal narcotics;
            ``(5) success in reducing crime associated with drug use in 
        the United States;
            ``(6) success in reducing the negative health and social 
        consequences of drug use in the United States; and
            ``(7) implementation of substance use disorder treatment 
        and prevention programs in the United States and improvements 
        in the adequacy and effectiveness of such programs.
    ``(c) Contents of the Annual Assessment.--The Director shall 
include in the annual assessment required under subsection (a)--
            ``(1) a summary of each evaluation received by the Director 
        under subsection (b);
            ``(2) a summary of the progress of each National Drug 
        Control Program Agency toward the National Drug Control 
        Strategy goals of the agency using the performance measures for 
        the agency developed under this chapter;
            ``(3) an assessment of the effectiveness of each National 
        Drug Control Program Agency and program in achieving the 
        National Drug Control Strategy for the previous year, including 
        a specific evaluation of whether the applicable goals, 
        measures, objectives, and targets for the previous year were 
        met;
            ``(4) for each National Drug Control Program Agency that 
        administers grant programs, an evaluation of the effectiveness 
        of each grant program, including an accounting of the funds 
        disbursed by the program in the prior year and a summary of how 
        those funds were used by the grantees and sub-grantees during 
        that period;
            ``(5) a detailed accounting of the amount of funds 
        obligated by each National Drug Control Program Agency in 
        carrying out the responsibilities of that agency under the 
        Strategy;
            ``(6) an assessment of the effectiveness of any Emerging 
        Threat Response Plan in effect for the previous year, including 
        a specific evaluation of whether the objectives and targets 
        were met and reasons for the success or failure of the previous 
        year's plan;
            ``(7) a detailed accounting of the amount of funds 
        obligated during the previous fiscal year for carrying out the 
        campaign under section 1009(d), including each recipient of 
        funds, the purpose of each expenditure, the amount of each 
        expenditure, any available outcome information, and any other 
        information necessary to provide a complete accounting of the 
        funds expended; and
            ``(8) the assessments required under this subsection shall 
        be based on the Performance Measurement System describe in 
        subsection (d).
    ``(d) Performance Measurement System.--The Director shall include 
in the annual assessment required under subsection (a) a national drug 
control performance measurement system, that--
            ``(1) develops annual, 2-year, and 5-year performance 
        measures, objectives, and targets for each National Drug 
        Control Strategy goal and objective established for reducing 
        drug use, availability, and the consequences of drug use;
            ``(2) describes the sources of information and data that 
        will be used for each performance measure incorporated into the 
        performance measurement system;
            ``(3) identifies major programs and activities of the 
        National Drug Control Program Agencies that support the goals 
        and annual objectives of the National Drug Control Strategy;
            ``(4) evaluates the contribution of demand reduction and 
        supply reduction activities implemented by each National Drug 
        Control Program Agency in support of the National Drug Control 
        Strategy;
            ``(5) monitors consistency between the drug-related goals, 
        measures, targets, and objectives of the National Drug Control 
        Program Agencies and ensures that each agency's goals and 
        budgets support, and are fully consistent with, the National 
        Drug Control Strategy; and
            ``(6) coordinates the development and implementation of 
        national drug control data collection and reporting systems to 
        support policy formulation and performance measurement, 
        including an assessment of--
                    ``(A) the quality of current drug use measurement 
                instruments and techniques to measure supply reduction 
                and demand reduction activities;
                    ``(B) the adequacy of the coverage of existing 
                national drug use measurement instruments and 
                techniques to measure the illicit drug user population 
                and groups that are at risk for illicit drug use;
                    ``(C) the adequacy of the coverage of existing 
                national treatment outcome monitoring systems to 
                measure the effectiveness of substance use disorder 
                treatment in reducing illicit drug use and criminal 
                behavior during and after the completion of substance 
                use disorder treatment; and
                    ``(D) the actions the Director shall take to 
                correct any deficiencies and limitations identified 
                pursuant to subparagraphs (A), (B), and (C).
    ``(e) Modifications.--A description of any modifications made 
during the preceding year to the national drug performance measurement 
system described in subsection (d) shall be included in each report 
submitted under subsection (a).
    ``(f) Annual Report on Consultation.--The Director shall include in 
the annual assessment required under subsection (a)--
            ``(1) a detailed description of how the Office has 
        consulted with and assisted State, local, and Tribal 
        governments with respect to the formulation and implementation 
        of the National Drug Control Strategy and other relevant 
        issues; and
            ``(2) a general review of the status of, and trends in, 
        demand reduction activities by private sector entities and 
        community-based organizations, including faith-based 
        organizations, to determine their effectiveness and the extent 
        of cooperation, coordination, and mutual support between such 
        entities and organizations and Federal, State, local, and 
        Tribal government agencies.
    ``(g) Performance-Budget Coordinator.--
            ``(1) Designation.--The Director shall designate or appoint 
        a United States Performance-Budget Coordinator to--
                    ``(A) ensure the Director has sufficient 
                information necessary to analyze the performance of 
                each National Drug Control Program Agency, the impact 
                Federal funding has had on the goals in the Strategy, 
                and the likely contributions to the goals of the 
                Strategy based on funding levels of each National Drug 
                Control Program Agency, to make an independent 
                assessment of the budget request of each agency under 
                section 1004;
                    ``(B) advise the Director on agency budgets, 
                performance measures and targets, and additional data 
                and research needed to make informed policy decisions 
                under sections 1004 and 1005; and
                    ``(C) other duties as may be determined by the 
                Director with respect to measuring or assessing 
                performance or agency budgets.
            ``(2) Determination of position.--The Director shall 
        determine whether the coordinator position is a noncareer 
        appointee in the Senior Executive Service or a career appointee 
        at the GS-15 level (or equivalent) or above.
``Sec. 1007. Monitoring and evaluation of national drug control program
    ``(a) In General.--The Director shall monitor implementation of the 
National Drug Control Program and the activities of the National Drug 
Control Program Agencies in carrying out the goals and objectives of 
the National Drug Control Strategy including--
            ``(1) conducting program and performance audits and 
        evaluations; and
            ``(2) requesting assistance from the Inspector General of 
        the relevant agency in such audits and evaluations.
    ``(b) Accounting of Funds Expended.--(1) Not later than February 1 
of each year, in accordance with guidance issued by the Director, the 
head of each National Drug Control Program Agency shall submit to the 
Director a detailed accounting of all funds expended by the agency for 
National Drug Control Program activities during the previous fiscal 
year and shall ensure such detailed accounting is authenticated for the 
previous fiscal year by the Inspector General for such agency prior to 
the submission to the Director as frequently as determined by the 
Inspector General but not less frequently that every 3 years.
    ``(2) The Director shall submit to Congress not later than April 1 
of each year the information submitted to the Director under paragraph 
(1).
    ``(c) Notification.--The Director shall notify any National Drug 
Control Program Agency if its activities are not in compliance with the 
responsibilities of the agency under the National Drug Control 
Strategy, transmit a copy of each such notification to the President 
and the appropriate congressional committees, and maintain a copy of 
each such notification.
    ``(d) Recommendations.--The Director shall make such 
recommendations to the President and the appropriate congressional 
committees as the Director determines are appropriate regarding changes 
in the organization, management, and budgets of the National Drug 
Control Program Agencies, and changes in the allocation of personnel to 
and within those agencies, to implement the policies, goals, 
objectives, and priorities established under section 1002(c)(1) and the 
National Drug Control Strategy.
    ``(e) Authorization, Development, and Implementation of a 
Coordinated Tracking System.--
            ``(1) Establishment.--The Director shall establish a 
        coordinated tracking system of federally-funded initiatives and 
        grant programs which shall--
                    ``(A) be the central repository of all drug control 
                grants;
                    ``(B) identify duplication, overlap, or gaps in 
                funding to provide increased accountability of 
                federally-funded grants for substance use disorder 
                treatment, prevention, and enforcement;
                    ``(C) identify impediments that applicants 
                currently have in the grant application process with 
                applicable agencies; and
                    ``(D) be developed and maintained by the Office 
                with the support of designated National Drug Control 
                Program Agencies and any other agency determined by the 
                Director.
            ``(2) Performance metrics.--The Director shall identify 
        metrics and achievable goals for grant recipients in 
        furtherance of the Strategy. Such metrics shall be used to 
        measure how effective each federally funded initiative is in 
        achieving the objectives of the Strategy and to enable 
        comparisons of federally funded initiatives to identify those 
        that are the most cost effective.
            ``(3) Grant application standardization.--To reduce the 
        administrative burden on grant applicants and improve oversight 
        of Federal funds, the Director, in consultation with the head 
        of each National Drug Control Program Agency, shall develop a 
        plan for coordinating and standardizing drug control grant 
        application processes and develop a joint application to be 
        used by all National Drug Control Program Agencies.
            ``(4) Central portal.--The Director shall maintain on the 
        public, electronic portal of the Office a list all drug control 
        grant programs available in a central location. The head of 
        each National Drug Control Program Agency shall provide a 
        complete list of all drug control program grant programs to the 
        Director and annually update such list.
            ``(5) Report to congress.--The Director shall include in 
        the assessment submitted to Congress under section 1006 an 
        assessment on progress under this section.
``Sec. 1008. Coordination and oversight of the national drug control 
              program
    ``(a) In General.--The Director shall coordinate and oversee the 
implementation by the National Drug Control Program Agencies of the 
policies, goals, objectives, and priorities established under section 
1002(c)(1) and the fulfillment of the responsibilities of such agencies 
under the National Drug Control Strategy and make recommendations to 
National Drug Control Program Agency heads with respect to 
implementation of National Drug Control Programs.
    ``(b) Detailing Employees to Other Agencies.--
            ``(1) Request.--The Director may request the head of an 
        agency or program of the Federal Government to place agency 
        personnel who are engaged in drug control activities on 
        temporary detail to another agency in order to implement the 
        National Drug Control Strategy.
            ``(2) Agency compliance.--The head of the agency shall 
        comply with any request made under paragraph (1).
            ``(3) Maximum number of detailees.--The maximum number of 
        personnel who may be detailed to another agency (including the 
        Office) under this subsection during any fiscal year is--
                    ``(A) for the Department of Defense, 50; and
                    ``(B) for any other agency, 10.
    ``(c) Directing Federal Funding.--The Director may transfer funds 
made available to a National Drug Control Program Agency for National 
Drug Control Strategy programs and activities to another account within 
such agency or to another National Drug Control Program Agency for 
National Drug Control Strategy programs and activities, except that--
            ``(1) the authority under this subsection may be limited in 
        an annual appropriations Act or other provision of Federal law;
            ``(2) the Director may exercise the authority under this 
        subsection only with the concurrence of the head of each 
        affected agency;
            ``(3) in the case of an interagency transfer, the total 
        amount of transfers under this subsection may not exceed 3 
        percent of the total amount of funds made available for 
        National Drug Control Strategy programs and activities to the 
        agency from which those funds are to be transferred;
            ``(4) funds transferred to an agency under this subsection 
        may only be used to increase the funding for programs or 
        activities authorized by law;
            ``(5) the Director shall--
                    ``(A) submit to the appropriate congressional 
                committees and any other applicable committee of 
                jurisdiction, a reprogramming or transfer request in 
                advance of any transfer under this subsection in 
                accordance with the regulations of each affected 
                agency; and
                    ``(B) annually submit to the appropriate 
                congressional committees a report describing the effect 
                of all transfers of funds made pursuant to this 
                subsection or section 1004(f) during the 12-month 
                period preceding the date on which the report is 
                submitted; and
            ``(6) funds may only be used for--
                    ``(A) expansion of demand reduction activities;
                    ``(B) interdiction of illicit drugs on the high 
                seas, in United States territorial waters, and at 
                United States ports of entry by officers and employees 
                of National Drug Control Program Agencies and domestic 
                and foreign law enforcement officers;
                    ``(C) accurate assessment and monitoring of 
                international drug production and interdiction programs 
                and policies;
                    ``(D) activities to facilitate and enhance the 
                sharing of domestic and foreign intelligence 
                information among National Drug Control Program 
                Agencies related to the production and trafficking of 
                drugs in the United States and foreign countries;
                    ``(E) activities to prevent the diversion of 
                prescription drugs for illicit use; and
                    ``(F) research related to any of these activities.
    ``(d) Directing Federal Funding to Respond to Emerging Threats.--
            ``(1) In general.--The Director may transfer funds made 
        available to a National Drug Control Program Agency for 
        National Drug Control Strategy programs and activities to 
        another account within such agency or to another National Drug 
        Control Program Agency for National Drug Control Strategy 
        programs and activities to implement the provisions of a plan 
        developed under section 1009, except that--
                    ``(A) the authority under this subsection may be 
                limited in an annual appropriations Act or other 
                provision of Federal law;
                    ``(B) the Director may exercise the authority under 
                this subsection only with the concurrence of the head 
                of each affected agency;
                    ``(C) in the case of an interagency transfer, the 
                total amount of transfers under this subsection may not 
                exceed 10 percent of the total amount of funds made 
                available for National Drug Control Strategy programs 
                and activities to the agency from which those funds are 
                to be transferred;
                    ``(D) funds transferred to an agency under this 
                subsection may only be used to increase the funding for 
                programs or activities authorized by law;
                    ``(E) no transfer of funds under this subsection 
                may result in a reduction in total Federal expenditures 
                for substance use disorder treatment;
                    ``(F) the Director shall--
                            ``(i) submit to the appropriate 
                        congressional committees and any other 
                        applicable committee of jurisdiction, a 
                        reprogramming or transfer request in advance of 
                        any transfer under this subsection in 
                        accordance with the regulations of each 
                        affected agency; and
                            ``(ii) annually submit to the appropriate 
                        congressional committees a report describing 
                        the effect of all transfers of funds made 
                        pursuant to this subsection or section 1004(f) 
                        during the 12-month period preceding the date 
                        on which the report is submitted; and
                    ``(G) funds may only be used for--
                            ``(i) expansion of demand reduction 
                        activities;
                            ``(ii) interdiction of illicit drugs on the 
                        high seas, in United States territorial waters, 
                        and at United States ports of entry by officers 
                        and employees of National Drug Control Program 
                        Agencies and domestic and foreign law 
                        enforcement officers;
                            ``(iii) accurate assessment and monitoring 
                        of international drug production and 
                        interdiction programs and policies;
                            ``(iv) activities to facilitate and enhance 
                        the sharing of domestic and foreign 
                        intelligence information among National Drug 
                        Control Program Agencies related to the 
                        production and trafficking of drugs in the 
                        United States and foreign countries;
                            ``(v) activities to prevent the diversion 
                        of prescription drugs for illicit use; and
                            ``(vi) research related to any of these 
                        activities.
            ``(2) Inadequacy of transfer.--In the event the authority 
        under this subsection is inadequate to implement the provisions 
        of a plan developed under section 1009, the Director shall 
        submit a request for funding to the appropriate congressional 
        committees within 30 days after the date on which the Director 
        determines there is a need for additional funding.
    ``(e) Fund Control Notices.--
            ``(1) In general.--The Director may issue to the head of a 
        National Drug Control Program Agency a fund control notice to 
        ensure compliance with the National Drug Control Program 
        Strategy. A fund control notice may direct that all or part of 
        an amount appropriated to the National Drug Control Program 
        Agency account be obligated by--
                    ``(A) months, fiscal year quarters, or other time 
                periods; and
                    ``(B) activities, functions, projects, or object 
                classes.
            ``(2) Unauthorized obligation or expenditure prohibited.--
        An officer or employee of a National Drug Control Program 
        Agency shall not make or authorize an expenditure or obligation 
        contrary to a fund control notice issued by the Director.
            ``(3) Disciplinary action for violation.--In the case of a 
        violation of paragraph (2) by an officer or employee of a 
        National Drug Control Program Agency, the head of the agency, 
        upon the request of and in consultation with the Director, may 
        subject the officer or employee to appropriate administrative 
        discipline, including, when circumstances warrant, suspension 
        from duty without pay or removal from office.
            ``(4) Congressional notice.--Not later than 5 days after 
        issuance of a fund control notice, the Director shall submit a 
        copy of such fund control notice to the appropriate 
        congressional committees and make such notice publicly 
        available.
            ``(5) Restrictions.--The Director may not issue a fund 
        control notice to direct that all or part of an amount 
        appropriated to the National Drug Control Program Agency 
        account be obligated, modified, or altered in any manner 
        contrary, in whole or in part, to a specific appropriation or 
        statute.
    ``(f) Exclusions.--The authorities described under subsections (c), 
(d), and (e) do not apply to any program under subchapter II or III.
    ``(g) Foreign Assistance Act Participation.--The Director may 
participate in the drug certification process pursuant to section 490 
of the Foreign Assistance Act of 1961 (22 U.S.C. 2291j) and section 706 
of the Department of State Authorization Act for Fiscal Year 2003 (22 
U.S.C. 229j-l).
    ``(h) Certifications of Policy Changes to Director.--
            ``(1) In general.--Subject to paragraph (2), the head of a 
        National Drug Control Program Agency shall, unless exigent 
        circumstances require otherwise, notify the Director in writing 
        regarding any proposed change in policies relating to the 
        activities of that agency under the National Drug Control 
        Program prior to implementation of such change. The Director 
        shall promptly review such proposed change and certify to the 
        head of that agency in writing whether such change is 
        consistent with the National Drug Control Strategy.
            ``(2) Exception.--If prior notice of a proposed change 
        under paragraph (1) is not practicable--
                    ``(A) the head of the National Drug Control Program 
                Agency shall notify the Director of the proposed change 
                as soon as practicable; and
                    ``(B) upon such notification, the Director shall 
                review the change and certify to the head of that 
                agency in writing whether the change is consistent with 
                the National Drug Control Strategy.
    ``(i) Work in Conjunction With Assistant for National Security 
Affairs.--The Director shall, in any matter affecting national security 
interests, work in conjunction with the Assistant to the President for 
National Security Affairs.
    ``(j) Authorities Not Derogated.--Nothing in this chapter shall be 
construed as derogating the authorities and responsibilities of the 
head of any agency, the Director of National Intelligence, or the 
Director of the Central Intelligence Agency contained in the National 
Security Act of 1947 (50 U.S.C. 401 et seq.), the Central Intelligence 
Agency Act of 1949 (50 U.S.C. 403a et seq.), or any other law.
``Sec. 1009. Emerging threats task force, plan, campaign
    ``(a) Emerging Threats Task Force.--
            ``(1) Emerging and continuing threats coordinator.--The 
        Director shall designate or appoint a United States Emerging 
        and Continuing Threats Coordinator to perform the duties of 
        that position described in this section and such other duties 
        as may be determined by the Director. The Director shall 
        determine whether the coordinator position is a noncareer 
        appointee in the Senior Executive Service or a career appointee 
        at the GS-15 level (or equivalent) or above.
            ``(2) Establishment and monitoring.--The Emerging and 
        Continuing Threats Coordinator (referred to in this section as 
        the `Coordinator') shall monitor evolving and emerging drug 
        threats in the United States and shall serve as Chair of an 
        Emerging Threats Task Force (in this section, referred to as 
        the `task force'). The Director shall appoint other members of 
        the task force, which shall include--
                    ``(A) representatives from National Drug Control 
                Program Agencies or other agencies;
                    ``(B) representatives from State, local, and Tribal 
                governments;
                    ``(C) the Director of the National Drug Control 
                Fusion Center established in section 1013; and
                    ``(D) representatives from other entities as 
                determined to be necessary by the Director.
            ``(3) Information review and sharing.--
                    ``(A) In general.--The task force shall disseminate 
                and facilitate the sharing with Federal, State, local, 
                and Tribal officials and other entities as determined 
                by the Director of pertinent information and data 
                relating to the following:
                            ``(i) Recent trends in drug supply and 
                        demand.
                            ``(ii) Fatal and nonfatal overdoses.
                            ``(iii) Demand for and availability of 
                        evidence-based substance use disorder 
                        treatment, including the extent of the unmet 
                        treatment need, and treatment admission trends.
                            ``(iv) Recent trends in drug interdiction, 
                        supply, and demand from State, local, and 
                        Tribal law enforcement agencies.
                            ``(v) Other subject matter as determined 
                        necessary by the Director.
                    ``(B) Contract, agreement, and other authority.--
                The Director may award contracts, enter into 
                interagency agreements, manage individual projects, and 
                conduct other activities in support of the 
                identification of emerging drug threats and in support 
                of the development, implementation, and assessment of 
                any Emerging Threat Response Plan.
                    ``(C) Data analysis activities.--In support of the 
                task force, the National Drug Control Fusion Center is 
                authorized to conduct and provide to the task force the 
                results of data analysis activities that the task force 
                requests to aid in their review of recent trends in the 
                data disseminated under subparagraph (A).
            ``(4) Criteria to identify emerging drug threats.--Not 
        later than 60 days after the date on which a task force first 
        meets, the task force shall develop and recommend to the 
        Director criteria to be used to identify an emerging drug 
        threat or the termination of an emerging drug threat 
        designation based on information gathered by the task force in 
        paragraph (2), statistical data, and other evidence.
            ``(5) Meetings.--The task force shall meet in person not 
        less frequently than quarterly and at additional meetings if 
        determined to be necessary by and at the call of the Chair to--
                    ``(A) identify and discuss evolving and emerging 
                drug trends in the United States using the criteria 
                established in paragraph (3);
                    ``(B) assist in the formulation of any plan 
                described in subsection (c);
                    ``(C) oversee implementation of the plan described 
                in subsection (c); and
                    ``(D) provide such other advice to the Coordinator 
                and Director concerning strategy and policies for 
                emerging drug threats and trends as the task force 
                determines to be appropriate.
    ``(b) Designation.--
            ``(1) In general.--The Director, in consultation with the 
        Coordinator, the task force, and the head of each National Drug 
        Control Program Agency, may designate an emerging drug threat 
        in the United States.
            ``(2) Standards for designation.--The Director, in 
        consultation with the Coordinator, shall promulgate and make 
        publicly available standards by which a designation under 
        paragraph (1) and the termination of such designation may be 
        made. In developing such standards, the Director shall consider 
        the recommendations of the task force and other criteria the 
        Director considers to be appropriate.
            ``(3) Public statement required.--The Director shall 
        publish a public written statement on the portal of the Office 
        explaining the designation of an emerging drug threat or the 
        termination of such designation and shall notify the 
        appropriate congressional committees of the availability of 
        such statement when a designation or termination of such 
        designation has been made.
    ``(c) Plan.--
            ``(1) Public availability of plan.--Not later than 60 days 
        after making a designation under subsection (b), the Director 
        shall publish and make publicly available an Emerging Threat 
        Response Plan and notify the President and the appropriate 
        congressional committees of such plan's availability.
            ``(2) Timing.--Not less frequently than every 90 days after 
        the date on which the plan is published under paragraph (1), 
        the Director shall update the plan and report on implementation 
        of the plan, until the Director issues the public statement 
        required under subsection (b)(3) to terminate the emerging drug 
        threat designation.
            ``(3) Contents of an emerging threat response plan.--The 
        Director shall include in the plan--
                    ``(A) a comprehensive strategic assessment of the 
                emerging drug threat, including the current 
                availability of, demand for, and effectiveness of 
                evidence-based prevention, treatment, and enforcement 
                programs and efforts to respond to the emerging drug 
                threat;
                    ``(B) comprehensive, research-based, long-range, 
                quantifiable goals for addressing the emerging drug 
                threat, including for reducing the supply of the drug 
                designated as the emerging drug threat and for 
                expanding the availability and effectiveness of 
                evidence-based substance use disorder treatment and 
                prevention programs to reduce the demand for the 
                emerging drug threat;
                    ``(C) performance measures pertaining to the plan's 
                goals, including quantifiable and measurable objectives 
                and specific targets;
                    ``(D) the level of funding needed to implement the 
                plan, including whether funding is available to be 
                reprogrammed or transferred to support implementation 
                of the plan or whether additional appropriations are 
                necessary to implement the plan;
                    ``(E) an implementation strategy for the education 
                and public awareness campaign under subsection (d), 
                including goals as described under subparagraph (B) and 
                performance measures, objectives, and targets, as 
                described under subparagraph (C); and
                    ``(F) any other information necessary to inform the 
                public of the status, progress, or response of an 
                emerging drug threat.
            ``(4) Implementation.--
                    ``(A) In general.--Not later than 90 days after the 
                date on which a designation is made under subsection 
                (b), the Director, in consultation with the President, 
                the appropriate congressional committees, and the head 
                of each National Drug Control Program Agency, shall 
                issue guidance on implementation of the plan described 
                in this subsection to the National Drug Control Program 
                Agencies and any other relevant agency determined to be 
                necessary by the Director.
                    ``(B) Coordinator's responsibilities.--The 
                Coordinator shall--
                            ``(i) direct the implementation of the plan 
                        among the agencies identified in the plan, 
                        State, local, and Tribal governments, and other 
                        relevant entities;
                            ``(ii) facilitate information-sharing 
                        between agencies identified in the plan, State, 
                        local, and Tribal governments, and other 
                        relevant entities; and
                            ``(iii) monitor implementation of the plan 
                        by coordinating the development and 
                        implementation of collection and reporting 
                        systems to support performance measurement and 
                        adherence to the plan by agencies identified in 
                        plan, where appropriate.
                    ``(C) Reporting.--Not later than 180 days after the 
                date on which a designation is made under subsection 
                (b) and in accordance with paragraph (2)(C), the head 
                of each agency identified in the plan shall submit to 
                the Coordinator a report on implementation of the plan.
    ``(d) Education and Public Awareness Campaign for Emerging Drug 
Threats.--
            ``(1) In general.--Not later than 90 days after the date on 
        which a designation is made under subsection (b), the Director 
        shall, to the extent feasible and appropriate, establish and 
        implement an evidence-based substance use prevention education 
        and public awareness campaign to inform the public about the 
        dangers of any drug designated as an emerging drug threat. Such 
        campaign shall--
                    ``(A) educate the public about the dangers of such 
                drug, including patient and family education about the 
                characteristics and hazards of such drug and methods to 
                safeguard against such dangers, including the safe 
                disposal of such drug;
                    ``(B) support evidence-based prevention programs 
                targeting audiences' attitudes, perceptions, and 
                beliefs concerning substance use and intentions to 
                initiate or continue such use;
                    ``(C) increase awareness of the negative 
                consequences of drug use;
                    ``(D) encourage individuals affected by substance 
                use disorders to seek treatment and provide such 
                individuals with information on how to recognize 
                addiction issues, what forms of evidence-based 
                treatment options are available, and how to access such 
                treatment; and
                    ``(E) combat the stigma of addiction and substance 
                use disorders, including the stigma of treating such 
                disorders with medication-assisted treatment therapies.
            ``(2) Consultation.--For the planning of the campaign under 
        paragraph (1), the Director shall consult with--
                    ``(A) the head of any appropriate National Drug 
                Control Program Agency to obtain advice on evidence-
                based scientific information for policy, program 
                development, and evaluation;
                    ``(B) experts in evidence-based media campaigns, 
                education, evaluation, and communication;
                    ``(C) experts on the designated drug;
                    ``(D) State, local, and Tribal government officials 
                and relevant agencies;
                    ``(E) the public;
                    ``(F) appropriate congressional committees; and
                    ``(G) any other affected person, as determined by 
                the Director.
            ``(3) Gifts and donations.--
                    ``(A) In general.--The Director may accept gifts 
                and donations (in cash or in kind, including voluntary 
                and uncompensated services or property), which shall be 
                available until expended, for the purpose of supporting 
                the education and public awareness campaign authorized 
                in this section, including the media campaign.
                    ``(B) Ethics guidelines.--The Director shall 
                establish written guidelines setting forth the criteria 
                to be used in determining whether a gift or donation 
                should be declined under this section because the 
                acceptance of the gift or donation would--
                            ``(i) reflect unfavorably upon the ability 
                        of the Director or the Office, or any employee 
                        of the Office, to carry out responsibilities or 
                        official duties under this chapter in a fair 
                        and objective manner; or
                            ``(ii) compromise the integrity or the 
                        appearance of integrity of programs or services 
                        provided under this chapter or of any official 
                        involved in those programs or services.
            ``(4) Implementation.--
                    ``(A) In general.--For any campaign established 
                under this subsection, the Director shall ensure the 
                following:
                            ``(i) Implementation is evidence-based, 
                        meets accepted standards for public awareness 
                        campaigns, and uses available resources in a 
                        manner to make the most progress toward 
                        achieving the goals identified in the Emerging 
                        Threats Response Plan and the requirements of 
                        paragraph (1).
                            ``(ii) Information disseminated through the 
                        campaign is accurate.
                            ``(iii) The Director approves the strategy 
                        of the campaign, all material distributed 
                        through the campaign, and the use of any 
                        Federal funds used for the campaign.
                            ``(iv) The campaign is designed using 
                        strategies found to be most effective at 
                        achieving such goals and requirements of 
                        paragraph (1), which may include--
                                    ``(I) a media campaign, as 
                                described in subparagraph (B);
                                    ``(II) local, regional, or 
                                population specific messaging;
                                    ``(III) establishing partnerships 
                                and promoting coordination among 
                                community stakeholders, including 
                                public, nonprofit organizations, and 
                                for profit entities;
                                    ``(IV) providing support, training, 
                                and technical assistance to establish 
                                and expand school and community 
                                prevention programs;
                                    ``(V) creating websites to 
                                publicize and disseminate information;
                                    ``(VI) conducting outreach and 
                                providing educational resources for 
                                parents;
                                    ``(VII) establishing State or 
                                regional advisory councils to provide 
                                input and recommendations to raise 
                                awareness regarding the drug designated 
                                as an emerging drug threat;
                                    ``(VIII) collaborating with law 
                                enforcement; and
                                    ``(IX) support for school-based 
                                public health education classes to 
                                improve teen knowledge about the 
                                effects of such designated drug.
                    ``(B) Media campaign.--Any campaign implemented 
                under this subsection may include a media component, 
                which--
                            ``(i) shall be designed to prevent the use 
                        of the drug designated as an emerging drug 
                        threat and to achieve the goals and 
                        requirements of paragraph (1);
                            ``(ii) shall be carried out through 
                        competitively awarded contracts to entities 
                        providing for the professional production and 
                        design of such campaign; and
                            ``(iii) may include the use of television, 
                        radio, Internet, social media, and other 
                        commercial marketing venues and may be targeted 
                        to specific age groups based on peer-reviewed 
                        social research.
                    ``(C) Required notice for communication from the 
                office.--Any communication, including an advertisement, 
                paid for or otherwise disseminated by the Office 
                directly or through a contract awarded by the Office 
                shall include a prominent notice informing the audience 
                that the communication was paid for by of the Office.
            ``(5) Evaluation.--
                    ``(A) Performance evaluation.--The Director shall 
                include an evaluation of the campaign in the annual 
                assessment under section 1006, which shall include the 
                following:
                            ``(i) A performance evaluation of the 
                        campaign, including progress toward meeting the 
                        goals, objectives, measures, and targets 
                        identified in the Emerging Threats Response 
                        Plan.
                            ``(ii) A description of all policies and 
                        practices to eliminate the potential for waste, 
                        fraud, abuse, and to ensure Federal funds are 
                        used responsibly.
                            ``(iii) A list of all contracts or other 
                        agreements entered into to implement the 
                        campaign.
                            ``(iv) The results of any financial audit 
                        of the campaign.
                            ``(v) A description of any evidence used to 
                        develop the campaign.
                            ``(vi) The sources and amount of each gift 
                        or donation accepted by the Office, and the 
                        source and amount of each gift or donation 
                        accepted by a contractor to be used in its 
                        performance of a contract for the campaign.
                    ``(B) Independent evaluation.--Not later than 180 
                days after establishing a campaign under paragraph (1) 
                and not less than frequently than every 2 years 
                thereafter, the Director shall--
                            ``(i) designate an independent entity to 
                        evaluate the effectiveness of the campaign with 
                        meeting the goals established in the Emerging 
                        Threat Response Plan and the requirements of 
                        paragraph (1); and
                            ``(ii) submit the results of the 
                        independent evaluation to the appropriate 
                        congressional committees.
            ``(6) Funding prohibitions.--None of the amounts made 
        available under this subsection may be obligated for any of the 
        following:
                    ``(A) To supplant current anti-drug community-based 
                coalitions.
                    ``(B) To supplant pro bono public service time 
                donated by national and local broadcasting network for 
                other public services campaigns.
                    ``(C) For partisan political purposes, or express 
                advocacy in support of or to defeat any clearly 
                identified candidate, clearly identified ballot 
                initiative, or clearly identified legislative or 
                regulatory proposal.
                    ``(D) For any advocacy in support of any particular 
                company, industry association, or advocacy group or the 
                explicit policy positions held by such groups.
                    ``(E) To direct any individuals to a specific type 
                of substance use disorder treatment, treatment 
                facility, medical provider, or form of medication 
                assisted treatment.
                    ``(F) To fund any advertising that features any 
                elected officials, persons seeking elected office, 
                cabinet level officials, or other Federal officials 
                employed pursuant to section 213 of Schedule C of title 
                5, Code of Federal Regulations.
    ``(e) Authorization of Appropriations.--There is authorized to be 
appropriated to the Office to carry out this section, $25 million for 
each of fiscal years 2019 through 2023.
``Sec. 1010. National and international coordination
    ``(a) Dissemination of Research and Information to States.--The 
Director shall ensure that drug control research and information is 
effectively disseminated by National Drug Control Program Agencies to 
State and local governments and nongovernmental entities involved in 
demand reduction by--
            ``(1) encouraging formal consultation between any such 
        agency that conducts or sponsors research, and any such agency 
        that disseminates information in developing research and 
        information product development agendas;
            ``(2) encouraging such agencies (as appropriate) to develop 
        and implement dissemination plans that specifically target 
        State and local governments and nongovernmental entities 
        involved in demand reduction; and
            ``(3) supporting the substance abuse information 
        clearinghouse administered by the Assistant Secretary for 
        Mental Health and Substance Use and established in section 
        501(d)(16) of the Public Health Service Act by--
                    ``(A) encouraging all National Drug Control Program 
                Agencies to provide all appropriate and relevant 
                information; and
                    ``(B) supporting the dissemination of information 
                to all interested entities.
    ``(b) Standards.--
            ``(1) Development.--The Director shall coordinate the 
        development of evidence-based standards developed by National 
        Drug Control Program Agencies and other relevant agencies and 
        non-Federal entities to State, local, and Tribal governments 
        and nongovernmental entities related to drug control policies, 
        practices, and procedures, such as the investigation of drug-
        related deaths, by--
                    ``(A) encouraging appropriate agencies and State, 
                local, and Tribal governments to develop data standards 
                for drug control practices and procedures and related 
                statistical data;
                    ``(B) encouraging information sharing between 
                appropriate agencies and State, local, and Tribal 
                governments of relevant drug control information and 
                data;
                    ``(C) establishing a working group of agencies, 
                State, local, and Tribal governments, and other 
                relevant stakeholders to discuss and develop such 
                standards; and
                    ``(D) facilitating collaboration among agencies, 
                non-Federal entities, States, local, and Tribal 
                governments, and nongovernmental agencies.
            ``(2) Implementation.--The Director shall promote the 
        implementation of the standards described in paragraph (1) by--
                    ``(A) encouraging adoption by providing the 
                standards to State and local governments through the 
                internet, annual publications or periodicals, and other 
                widely-disseminated means; and
                    ``(B) facilitating the use and dissemination of 
                such standards among State and local governments by--
                            ``(i) providing technical assistance to 
                        State, local, and Tribal governments seeking to 
                        adopt or implement such standards; and
                            ``(ii) coordinating seminars and training 
                        sessions for State, local, and Tribal 
                        governments seeking to adopt or implement such 
                        standards.
    ``(c) Private Sector.--
            ``(1) In general.--The Director or the head of a National 
        Drug Control Program (as designated by the Director) shall 
        coordinate with the private sector to promote private research 
        and development of medications to treat or prevent addiction, 
        including research and development for non-addictive pain 
        management medication, abuse deterrent formulations, 
        medication-assisted treatment, and other addiction research 
        determined to be necessary by the Director by--
                    ``(A) encouraging the sharing of information 
                regarding evidence-based treatment addiction findings 
                and related data between agencies and the private 
                sector, as appropriate;
                    ``(B) encouraging collaboration between appropriate 
                agencies and the private sector; and
                    ``(C) providing private sector entities with 
                relevant statistical data and information to enhance 
                research as permissible.
            ``(2) Working group.--The Director may establish a working 
        group of National Drug Control Program Agencies, State, local, 
        and Tribal governments, and the private sector stakeholders to 
        discuss and disseminate best practices, research and 
        development, and other related issues, as appropriate.
    ``(d) Model Acts Program.--
            ``(1) In general.--The Director shall provide for or shall 
        enter into an agreement with a nonprofit organization to--
                    ``(A) advise States on establishing laws and 
                policies to address illicit drug use issues; and
                    ``(B) revise such model State drug laws and draft 
                supplementary model State laws to take into 
                consideration changes in illicit drug use issues in the 
                State involved.
            ``(2) Authorization of appropriations.--There is authorized 
        to be appropriated to carry out this subsection $1.25 million 
        for each of fiscal years 2019 through 2023.
    ``(e) Drug Court Training and Technical Assistance Program.--
            ``(1) Grants authorized.--The Director may make a grant to 
        a nonprofit organization for the purpose of providing training 
        and technical assistance to drug courts.
            ``(2) Authorization of appropriations.--There is authorized 
        to be appropriated to carry out this subsection $2 million for 
        each of fiscal years 2019 through 2023.
    ``(f) International Coordination.--The Director may facilitate 
international drug control coordination efforts.
    ``(g) State, Local, and Tribal Affairs Coordinator.--The Director 
shall designate or appoint a United States State, Local, and Tribal 
Affairs Coordinator to perform the duties of the Office outlined in 
this section and section 1005 and such other duties as may be 
determined by the Director with respect to coordination of drug control 
efforts between agencies and State, local, and Tribal governments. The 
Director shall determine whether the coordinator position is a 
noncareer appointee in the Senior Executive Service or a career 
appointee at the GS-15 level (or equivalent) or above.
``Sec. 1011. Interdiction
    ``(a) United States Interdiction Coordinator.--
            ``(1) In general.--The Director shall designate or appoint 
        a noncareer appointee in the Senior Executive Service or a 
        career appointee at the GS-15 level (or equivalent) or above as 
        the United States Interdiction Coordinator to perform the 
        duties of that position described in paragraph (2) and such 
        other duties as may be determined by the Director with respect 
        to coordination of efforts to interdict illicit drugs from 
        entering the United States.
            ``(2) Responsibilities.--The United States Interdiction 
        Coordinator shall be responsible to the Director for--
                    ``(A) coordinating the interdiction activities of 
                the National Drug Control Program Agencies to ensure 
                consistency with the National Drug Control Strategy;
                    ``(B) on behalf of the Director, developing and 
                issuing, on or before September 1 of each year and in 
                accordance with paragraph (4), a National Interdiction 
                Command and Control Plan to ensure the coordination and 
                consistency described in subparagraph (A);
                    ``(C) assessing the sufficiency of assets committed 
                to illicit drug interdiction by the relevant National 
                Drug Control Program Agencies; and
                    ``(D) advising the Director on the efforts of each 
                National Drug Control Program Agency to implement the 
                National Interdiction Command and Control Plan.
            ``(3) Staff.--The Director shall assign such permanent 
        staff of the Office as he considers appropriate to assist the 
        United States Interdiction Coordinator to carry out the 
        responsibilities described in paragraph (2), and may request 
        that appropriate National Drug Control Program Agencies detail 
        or assign staff to assist in carrying out such activities.
            ``(4) National interdiction command and control plan.--
                    ``(A) Purposes.--The National Interdiction Command 
                and Control Plan--
                            ``(i) shall set forth the Government's 
                        strategy for drug interdiction;
                            ``(ii) shall state the specific roles and 
                        responsibilities of the relevant National Drug 
                        Control Program Agencies for implementing that 
                        strategy; and
                            ``(iii) shall identify the specific 
                        resources required to enable the relevant 
                        National Drug Control Program Agencies to 
                        implement that strategy.
                    ``(B) Consultation with other agencies.--Before the 
                submission of the National Drug Control Strategy or 
                annual supplement required under section 1005(d), as 
                applicable, the United States Interdiction Coordinator 
                shall issue the National Interdiction Command and 
                Control Plan, in consultation with the other members of 
                the Interdiction Committee described in subsection (b).
                    ``(C) Report to congress.--On or before September 1 
                of each year, the Director, through the United States 
                Interdiction Coordinator, shall provide to the 
                appropriate congressional committees, to the Committee 
                on Armed Services and the Committee on Homeland 
                Security of the House of Representatives, and to the 
                Committee on Homeland Security and Governmental Affairs 
                and the Committee on Armed Services of the Senate, a 
                report that--
                            ``(i) includes--
                                    ``(I) a copy of that year's 
                                National Interdiction Command and 
                                Control Plan;
                                    ``(II) information for the previous 
                                10 years regarding the number and type 
                                of seizures of drugs by each National 
                                Drug Control Program Agency conducting 
                                drug interdiction activities and 
                                statistical information on the 
                                geographic areas of such seizures; and
                                    ``(III) information for the 
                                previous 10 years regarding the number 
                                of air and maritime patrol hours 
                                undertaken by each National Drug 
                                Control Program Agency conducting drug 
                                interdiction activities and statistical 
                                information on the geographic areas in 
                                which such patrol hours took place; and
                            ``(ii) may include recommendations about 
                        changes to existing agency authorities or laws 
                        governing interagency relationships.
                    ``(D) Classified annex.--The report submitted 
                pursuant to subparagraph (C) may include a classified 
                annex.
    ``(b) Interdiction Committee.--
            ``(1) In general.--The Interdiction Committee shall meet 
        to--
                    ``(A) discuss and resolve issues related to the 
                coordination, oversight, and integration of 
                international, border, and domestic drug interdiction 
                efforts in support of the National Drug Control 
                Strategy;
                    ``(B) review the annual National Interdiction 
                Command and Control Plan, and provide advice to the 
                Director and the United States Interdiction Coordinator 
                concerning that plan; and
                    ``(C) provide such other advice to the Director 
                concerning drug interdiction strategy and policies as 
                the committee determines is appropriate.
            ``(2) Chair.--The Director shall designate one of the 
        members of the Interdiction Committee to serve as Chair.
            ``(3) Meetings.--The members of the Interdiction Committee 
        shall meet, in person and not through any delegate or 
        representative, at least once per calendar year, before June 1. 
        At the call of the Director or the Chair, the Interdiction 
        Committee may hold additional meetings, which shall be attended 
        by the members in person, or through such delegates or 
        representatives as the members may choose.
            ``(4) Report.--Not later than September 30 of each year, 
        the Chair of the Interdiction Committee shall submit to the 
        Director and to the appropriate congressional committees a 
        report describing the results of the meetings and any 
        significant findings of the committee during the previous 12 
        months. Such report may include a classified annex.
``Sec. 1012. Treatment coordinator
    ``(a) United States Treatment Coordinator.--
            ``(1) In general.--The Director shall designate or appoint 
        a noncareer appointee in the Senior Executive Service or a 
        career appointee at the GS-15 level (or equivalent) or above as 
        the United States Treatment Coordinator to perform the 
        responsibilities of that position described in paragraph (2) 
        and such other duties as may be determined by the Director with 
        respect to coordination of efforts to expand the availability 
        of substance use disorder treatment with the goal of 
        eliminating the unmet treatment need.
            ``(2) Responsibilities.--The United States Treatment 
        Coordinator shall be responsible to the Director for--
                    ``(A) coordinating the activities of the National 
                Drug Control Program Agencies undertaken to expand the 
                availability of evidence-based substance use disorder 
                treatment to ensure consistency with the National Drug 
                Control Strategy;
                    ``(B) on behalf of the Director, developing and 
                issuing, on or before September 1 of each year and in 
                accordance with paragraph (4), a National Treatment 
                Plan to ensure the coordination and consistency 
                described in subparagraph (A);
                    ``(C) assessing the sufficiency of Federal 
                resources directed to substance use disorder treatment 
                by the relevant National Drug Control Program Agencies;
                    ``(D) encouraging the adoption by all substance use 
                disorder treatment providers of evidence-based 
                standards to guide all aspects of treatment provided; 
                and
                    ``(E) advising the Director on the efforts of each 
                National Drug Control Program Agency to implement the 
                National Treatment Plan.
            ``(3) Staff.--The Director shall assign such permanent 
        staff of the Office of the United States Treatment Coordinator 
        as the Director determines to be appropriate to assist the 
        United States Treatment Coordinator to carry out the 
        responsibilities described in paragraph (2), and may request 
        that appropriate National Drug Control Program Agencies detail 
        or assign staff to assist in carrying out such 
        responsibilities.
            ``(4) National treatment plan.--
                    ``(A) Purposes.--The National Treatment Plan--
                            ``(i) shall identify the unmet need for 
                        treatment for evidence-based substance use 
                        disorders and set forth the Government's 
                        strategy for closing the gap between available 
                        and needed treatment through all sources;
                            ``(ii) shall describe the specific roles 
                        and responsibilities of the relevant National 
                        Drug Control Program Agencies for implementing 
                        that strategy;
                            ``(iii) shall identify the specific 
                        resources required to enable the relevant 
                        National Drug Control Program Agencies to 
                        implement that strategy;
                            ``(iv) shall identify the resources, 
                        including private sources, required to 
                        eliminate the unmet need for evidence-based 
                        substance use disorder treatment; and
                            ``(v) may include recommendations about 
                        changes to existing agency authorities or laws 
                        governing interagency relationships.
                    ``(B) Consultation with other agencies.--Before the 
                submission of the National Treatment Strategy or annual 
                supplement required under section 1005(d), as 
                applicable, the United States Treatment Coordinator 
                shall issue the National Treatment Plan, in 
                consultation with the other members of the Treatment 
                Committee described in subsection (b).
                    ``(C) Report to congress.--On or before September 1 
                of each year, the Director, through the United States 
                Treatment Coordinator, shall provide to the appropriate 
                congressional committees a report that includes a copy 
                of that year's National Treatment Plan.
    ``(b) Treatment Committee.--
            ``(1) In general.--The Treatment Committee shall meet to--
                    ``(A) review and discuss the adequacy of evidence-
                based substance use disorder treatment as well as the 
                unmet need for treatment;
                    ``(B) review and discuss the status of the 
                implementation of the National Treatment Plan; and
                    ``(C) provide such other advice to the Director 
                concerning substance use disorder treatment initiatives 
                as the committee determines is appropriate.
            ``(2) Chair.--The Director shall designate one of the 
        members of the Treatment Committee to serve as Chair.
            ``(3) Meetings.--The members of the Treatment Committee 
        shall meet, in person and not through any delegate or 
        representative, at least once per calendar year, before June 1. 
        At the call of the Director or the Chair, the Treatment 
        Committee may hold additional meetings, which shall be attended 
        by the members in person, or through such delegates or 
        representatives as the members may choose.
            ``(4) Report.--Not later than September 30 of each year, 
        the Chair of the Treatment Committee shall submit to the 
        Director and to the appropriate congressional committees a 
        report describing the results of the meetings and any 
        significant findings of the committee during the previous 12 
        months. Such report may include a classified annex.
``Sec. 1013. Critical information coordination
    ``(a) National Drug Control Fusion Center.--
            ``(1) Establishment.--The Director shall, in consultation 
        with the head of each National Drug Control Program Agency, 
        designate an agency to establish a National Drug Control Fusion 
        Center (referred to in this section as the `Center'). The 
        Center shall operate under the authority of the Director and 
        shall work with the National Drug Control Program Agencies to 
        collect, compile, analyze, and facilitate the sharing of data 
        on the use of illicit drugs, treatment for substance use 
        disorder, and interdiction of illicit drugs. The Center shall 
        be considered a `statistical agency or unit', as that term is 
        defined in section 502 of the Confidential Information 
        Protection and Statistical Efficiency Act of 2002 (44 U.S.C. 
        3501 note) and shall have the necessary independence to ensure 
        any data or information acquired by an agency under a pledge of 
        confidentiality and for exclusively statistical purposes is 
        used exclusively for statistical purposes.
            ``(2) Center director.--There shall be at the head of the 
        Center a Center Director who shall be appointed by the Director 
        from among individuals qualified and distinguished in data 
        governance and statistical analysis.
            ``(3) Data compilation.--The Director, acting through the 
        Center Director, shall do the following:
                    ``(A) Coordinate data collection activities among 
                the National Drug Control Program Agencies.
                    ``(B) Collect information not otherwise collected 
                by National Drug Control Program Agencies as necessary 
                to inform the National Drug Control Strategy.
                    ``(C) Compile and analyze any data required to be 
                collected under this chapter.
                    ``(D) Disseminate technology, as appropriate, to 
                States and local jurisdictions to enable or improve the 
                collection of data on drug use, including the 
                recordation of the occurrence of fatal and non-fatal 
                drug overdoses.
                    ``(E) Compile information collected by National 
                Drug Control Program Agencies on grants issued through 
                any National Drug Control Program, including for any 
                grant the following:
                            ``(i) The recipient.
                            ``(ii) The amount.
                            ``(iii) The intended purpose.
                            ``(iv) Any evidence of the efficacy of the 
                        outcomes achieved by the program funded through 
                        the grant.
                            ``(v) Any assessments of how the grant met 
                        its intended purpose.
            ``(4) Toxicology screening.--
                    ``(A) Establishment.--The Center Director may 
                establish a toxicology screening program that engages 
                in--
                            ``(i) secondary analysis of urine samples 
                        that would otherwise be discarded by--
                                    ``(I) hospitals and substance use 
                                disorder treatment programs;
                                    ``(II) correctional facilities, 
                                booking sites, probation programs, drug 
                                courts, and related facilities; and
                                    ``(III) coroners and medical 
                                examiners; and
                            ``(ii) analysis of other physical samples, 
                        as determined by the Center Director to be 
                        valuable for understanding the prevalence of 
                        any illicit drug.
                    ``(B) De-identification of information.--The Center 
                Director shall ensure that no samples have any 
                personally identifiable information prior to 
                collection.
                    ``(C) Limitation on use.--No data obtained from 
                analysis conducted under this paragraph may be used as 
                evidence in any proceeding.
                    ``(D) State program.--The Center Director may 
                establish a program that enables States and local 
                jurisdictions to submit up to 20 urine samples per year 
                for toxicology analysis for the purposes of identifying 
                substances present in individuals who have suffered 
                fatal drug overdoses.
            ``(5) Authority to contract.--The Director may award 
        contracts, enter into interagency agreements, manage individual 
        projects, and conduct other operational activities under this 
        subsection.
    ``(b) Critical Drug Control Information and Evidence Plan.--
            ``(1) In general.--Not later than the first Monday in 
        February of each year, the Director shall submit to Congress a 
        systematic plan for increasing data collection to enable real-
        time surveillance of drug control threats, developing analysis 
        and monitoring capabilities, and identifying and addressing 
        policy questions relevant to the National Drug Control Policy, 
        Strategy, and Program. Such plan shall be made available on the 
        public online portal of the Office, shall cover at least a 4-
        year period beginning with the first fiscal year following the 
        fiscal year in which the plan is submitted and published, and 
        contain the following:
                    ``(A) A list of policy-relevant questions for which 
                the Director and each National Drug Control Program 
                Agency intends to develop evidence to support the 
                National Drug Control Program and Strategy.
                    ``(B) A list of data the Director and each National 
                Drug Control Program Agency intends to collect, use, or 
                acquire to facilitate the use of evidence in drug 
                control policymaking and monitoring.
                    ``(C) A list of methods and analytical approaches 
                that may be used to develop evidence to support the 
                National Drug Control Program and Strategy and related 
                policy.
                    ``(D) A list of any challenges to developing 
                evidence to support policymaking, including any 
                barriers to accessing, collecting, or using relevant 
                data.
                    ``(E) A description of the steps the Director and 
                the head of each National Drug Control Program Agency 
                will take to effectuate the plan.
                    ``(F) Any other relevant information as determined 
                by the Director.
            ``(2) Consultation.--In developing the plan required under 
        paragraph (1), the Director shall consult with the following:
                    ``(A) The public.
                    ``(B) Any evaluation or analysis units and 
                personnel of the Office.
                    ``(C) Office officials responsible for implementing 
                privacy policy.
                    ``(D) Office officials responsible for data 
                governance.
                    ``(E) The appropriate congressional committees.
                    ``(F) Any other individual or entity as determined 
                by the Director.
    ``(c) Evidence-Based Policy.--
            ``(1) Harm reduction programs.--When developing the 
        national drug control policy, any policy of the Director, 
        including policies relating to syringe exchange programs for 
        intravenous drug users, shall be based on the best available 
        medical and scientific evidence regarding the effectiveness of 
        such policy in promoting individual health, preventing the 
        spread of infectious disease and the impact of such policy on 
        drug addiction and use. In making any policy relating to harm 
        reduction programs, the Director shall consult with the 
        National Institutes of Health and the National Academy of 
        Sciences.
            ``(2) Fund restriction for the legalization of controlled 
        substances.--The Director shall ensure that no Federal funds 
        appropriated to the Office shall be expended for any study or 
        contract relating to the legalization (for a medical use or any 
        other use) for which a listing in schedule I is in effect under 
        section 202 of the Controlled Substances Act (21 U.S.C. 812).
    ``(d) Drug Control Data Dashboard.--
            ``(1) Establishment.--The Director, in consultation with 
        the Center Director, shall establish and maintain a data 
        dashboard on the online portal of the Office to be known as the 
        `Drug Control Data Dashboard'. The Director shall ensure the 
        user interface of the dashboard is constructed with modern 
        design standards. To the extent practicable, the data made 
        available on the dashboard shall be publicly available in a 
        machine-readable format and searchable by year, agency, drug, 
        and location.
            ``(2) Data.--The data included in the Drug Control Data 
        Dashboard shall be updated quarterly to the extent practicable, 
        but not less frequently than annually and shall include, at a 
        minimum, the following:
                    ``(A) For each substance identified under section 
                1005(c)(1)(A)(i)--
                            ``(i) the total amount seized and disrupted 
                        in the calendar year and each of the previous 3 
                        calendar years, including to the extent 
                        practicable the amount seized by State, local, 
                        and Tribal governments;
                            ``(ii) the known and estimated flows into 
                        the United States from all sources in the 
                        calendar year and each of the previous 3 
                        calendar years;
                            ``(iii) the total amount of known flows 
                        that could not be interdicted or disrupted in 
                        the calendar year and each of the previous 3 
                        calendar years;
                            ``(iv) the known and estimated levels of 
                        domestic production in the calendar year and 
                        each of the previous 3 calendar years, 
                        including the levels of domestic production if 
                        the drug is a prescription drug, as determined 
                        under the Federal Food, Drug, and Cosmetic Act, 
                        for which a listing is in effect under section 
                        202 of the Controlled Substances Act (21 U.S.C. 
                        812);
                            ``(v) the average street price for the 
                        calendar year and the highest known street 
                        price during the preceding 10-year period; and
                            ``(vi) to the extent practicable, related 
                        prosecutions by State, local, and Tribal 
                        governments.
                    ``(B) For the calendar year and each of the 
                previous 3 years data sufficient to show, disaggregated 
                by State and, to the extent feasible, by region within 
                a State, county, or city, the following:
                            ``(i) The number of fatal and non-fatal 
                        overdoses caused by each drug identified under 
                        subparagraph (A)(i).
                            ``(ii) The prevalence of substance use 
                        disorders.
                            ``(iii) The number of individuals who have 
                        received substance use disorder treatment, 
                        including medication assisted treatment, for a 
                        substance use disorder, including treatment 
                        provided through publicly-financed health care 
                        programs.
                            ``(iv) The extent of the unmet need for 
                        substance use disorder treatment, including the 
                        unmet need for medication-assisted treatment.
                    ``(C) Data sufficient to show the extent of 
                prescription drug diversion, trafficking, and misuse in 
                the calendar year and each of the previous 3 calendar 
                years.
                    ``(D) Any quantifiable measures the Director 
                determines to be appropriate to detail progress toward 
                the achievement of the goals of the National Drug 
                Control Strategy.
    ``(e) Access to Information.--
            ``(1) In general.--Upon the request of the Director, the 
        head of any National Drug Control Program Agency shall 
        cooperate with and provide to the Director any statistics, 
        studies, reports, and other information prepared or collected 
        by the agency concerning the responsibilities of the agency 
        under the National Drug Control Strategy that relate to--
                    ``(A) drug control; or
                    ``(B) the manner in which amounts made available to 
                that agency for drug control are being used by that 
                agency.
            ``(2) Protection of intelligence information.--
                    ``(A) In general.--The authorities conferred on the 
                Office and the Director by this chapter shall be 
                exercised in a manner consistent with provisions of the 
                National Security Act of 1947 (50 U.S.C. 401 et seq.). 
                The Director of National Intelligence shall prescribe 
                such regulations as may be necessary to protect 
                information provided pursuant to this chapter regarding 
                intelligence sources and methods.
                    ``(B) Duties of director.--The Director of National 
                Intelligence and the Director of the Central 
                Intelligence Agency shall, to the maximum extent 
                practicable in accordance with subparagraph (A), render 
                full assistance and support to the Office and the 
                Director.
            ``(3) Required reports from national drug control program 
        agencies.--The head of each National Drug Control Program 
        Agency shall submit to the Director such information and 
        reports as requested from such National Drug Control Program 
        Agency by the Director, which shall include from the 
        appropriate National Drug Control Program Agencies:
                    ``(A) Not later than July 1 of each year, the head 
                of a National Drug Control Program Agency designated by 
                the Director shall submit to the Director and the 
                appropriate congressional committees an assessment of 
                the quantity of illegal drug cultivation and 
                manufacturing in the United States on lands owned or 
                under the jurisdiction of their respective agencies 
                that was seized or eradicated by their personnel during 
                the preceding calendar year.
                    ``(B) Not later than July 1 of each year, the head 
                of a designated National Drug Control Program Agency 
                shall submit to the Director and the appropriate 
                congressional committees information for the preceding 
                year regarding--
                            ``(i) the number and type of seizures of 
                        drugs by each component of the agency seizing 
                        drugs, as well as statistical information on 
                        the geographic areas of such seizures; and
                            ``(ii) the number of air and maritime 
                        patrol hours primarily dedicated to drug supply 
                        reduction missions undertaken by each component 
                        of the agency.
                    ``(C) Not later than July 1 of each year, the head 
                of a designated National Drug Control Program Agency 
                shall submit to the Director and the appropriate 
                congressional committees information for the preceding 
                year regarding the number of air and maritime patrol 
                hours primarily dedicated to drug supply reduction 
                missions undertaken by each component of the agency.
                    ``(D) Not later than July 1 of each year, the head 
                of a designated National Drug Control Program Agency 
                shall submit to the Director and the appropriate 
                congressional committees information for the preceding 
                year regarding the number and type of--
                            ``(i) arrests for drug violations;
                            ``(ii) prosecutions by United States 
                        Attorneys for drug violations; and
                            ``(iii) seizures of drugs by each component 
                        of the Department of Justice seizing drugs, as 
                        well as statistical information on the 
                        geographic areas of such seizures.
    ``(f) Data Exchange Standards for Improved Interoperability.--
            ``(1) Interagency and intergovernmental designation and use 
        of data exchange standards working group.--The Director shall 
        establish a working group of National Drug Control Program 
        Agencies, State, local and Tribal government health and law 
        enforcement agencies, and data governance experts to develop 
        consensus data exchange standards for necessary categories of 
        information that allow effective electronic exchange of 
        information between States, between State agencies, between 
        States and National Drug Control Program Agencies, and any 
        other drug control relevant data exchange.
            ``(2) Data exchange standards must be nonproprietary and 
        interoperable.--The data exchange standards developed under 
        paragraph (1) shall, to the extent practicable, be 
        nonproprietary and interoperable.
            ``(3) Other requirements.--In developing data exchange 
        standards under this subsection, the working group shall, to 
        the extent practicable, incorporate--
                    ``(A) interoperable standards developed and 
                maintained by an international voluntary consensus 
                standards body, as defined by the Office of Management 
                and Budget;
                    ``(B) interoperable standards developed and 
                maintained by intergovernmental partnerships; and
                    ``(C) interoperable standards developed and 
                maintained by Federal entities with authority over 
                contracting and financial assistance.
            ``(4) Data exchange standards for federal reporting.--
                    ``(A) Designation.--The Director may, in 
                consultation with the working group established under 
                this subsection, National Drug Control Program 
                Agencies, and State, local, and Tribal governments, 
                designate data exchange standards to govern Federal 
                reporting and exchange requirements for National Drug 
                Control Programs, as appropriate.
                    ``(B) Requirements.--The data exchange reporting 
                standards designated under subparagraph (A) shall, to 
                the extent practicable--
                            ``(i) incorporate a widely accepted, 
                        nonproprietary, searchable, machine-readable 
                        format;
                            ``(ii) be consistent with and implement 
                        applicable accounting principles;
                            ``(iii) be implemented in a manner that is 
                        cost-effective and improves program efficiency 
                        and effectiveness; and
                            ``(iv) be capable of being continually 
                        upgraded as necessary.
                    ``(C) Incorporation of nonproprietary standards.--
                In designating data exchange standards under this 
                paragraph, the Director shall, to the extent 
                practicable, incorporate existing nonproprietary 
                standards.
                    ``(D) Rule of construction.--Nothing in this 
                paragraph shall be construed to require a change to 
                existing data exchange standards for Federal reporting 
                about a program referred to in this section, if the 
                head of the agency responsible for administering the 
                program finds the standards to be effective and 
                efficient.
            ``(5) Termination.--The working group established under 
        paragraph (1) shall terminate not earlier than 60 days after 
        the public notification of termination by the Director.
    ``(g) Annual Data Collection and Dissemination Requirements.--
            ``(1) In general.--The Director shall collect and 
        disseminate, as appropriate, such information as the Director 
        determines is appropriate, but not less than the information 
        described in this subsection. To the extent practicable, the 
        data shall be publicly available in a machine-readable format 
        on the Drug Control Data Dashboard, be searchable by year, 
        agency, drug, and location, and cover not less than the 
        previous 10-year period.
            ``(2) Preparation and dissemination of information.--The 
        Director shall prepare and disseminate the following:
                    ``(A) An assessment of current illicit drug use 
                (including inhalants and steroids) and availability, 
                impact of illicit drug use, and treatment availability, 
                which assessment shall include--
                            ``(i) estimates of drug prevalence and 
                        frequency of use as measured by national, 
                        State, and local surveys of illicit drug use 
                        and by other special studies of nondependent 
                        and dependent illicit drug use;
                            ``(ii) illicit drug use in the workplace 
                        and the productivity lost by such use; and
                            ``(iii) illicit drug use by arrestees, 
                        probationers, and parolees.
                    ``(B) An assessment of the reduction of illicit 
                drug availability, for each drug identified under 
                section 1005(c)(1)(A)(i), as measured by--
                            ``(i) the quantities of such drug available 
                        for consumption in the United States;
                            ``(ii) the amount of such drug entering the 
                        United States;
                            ``(iii) the number of illicit drug 
                        manufacturing laboratories seized and destroyed 
                        of each such drug and the number of hectares 
                        cultivated and destroyed domestically and in 
                        other countries of such drug;
                            ``(iv) the number of metric tons of such 
                        drug seized; and
                            ``(v) changes in the price and purity of 
                        such drug.
                    ``(C) An assessment of the reduction of the 
                consequences of illicit drug use and availability, 
                which shall include--
                            ``(i) the cost of treating substance use 
                        disorder in the United States, such as the 
                        quantity of illicit drug-related services 
                        provided;
                            ``(ii) the annual national health care cost 
                        of illicit drug use; and
                            ``(iii) the extent of illicit drug-related 
                        crime and criminal activity.
                    ``(D) A determination of the status of substance 
                use disorder treatment in the United States, by 
                assessing--
                            ``(i) public and private treatment 
                        utilization; and
                            ``(ii) the number of illicit drug users the 
                        Director estimates meet diagnostic criteria for 
                        treatment.
``Sec. 1014. Authorization of appropriations
    ``There are authorized to be appropriated to carry out this 
chapter, except as otherwise specified, to remain available until 
expended, $18.4 million for each of fiscal years 2019 through 2023.

         ``SUBCHAPTER II--DRUG-FREE COMMUNITIES SUPPORT PROGRAM

``Sec. 1021. Establishment of drug-free communities support program
    ``(a) Establishment.--The Director shall establish a program to 
support communities in the development and implementation of 
comprehensive, long-term plans and programs to prevent and treat 
substance use and misuse among youth.
    ``(b) Program.--In carrying out the Program, the Director shall--
            ``(1) make and track grants to grant recipients;
            ``(2) provide for technical assistance and training, data 
        collection, and dissemination of information on state-of-the-
        art practices that the Director determines to be effective in 
        reducing substance use; and
            ``(3) provide for the general administration of the 
        Program.
    ``(c) Administration.--The Director shall appoint an Administrator 
to carry out the Program.
    ``(d) Contracting.--The Director may employ any necessary staff and 
may enter into contracts or agreements with National Drug Control 
Program Agencies, including interagency agreements, to delegate 
authority for the execution of grants and for such other activities 
necessary to carry out this chapter.
``Sec. 1022. Program authorization
    ``(a) Grant Eligibility.--To be eligible to receive an initial 
grant or a renewal grant under this subchapter, a coalition shall meet 
each of the following criteria:
            ``(1) Application.--The coalition shall submit an 
        application to the Administrator in accordance with section 
        1023(a)(2).
            ``(2) Major sector involvement.--
                    ``(A) In general.--The coalition shall consist of 
                one or more representatives of each of the following 
                categories:
                            ``(i) Youth.
                            ``(ii) Parents.
                            ``(iii) Businesses.
                            ``(iv) The media.
                            ``(v) Schools.
                            ``(vi) Organizations serving youth.
                            ``(vii) Law enforcement.
                            ``(viii) Religious or fraternal 
                        organizations.
                            ``(ix) Civic and volunteer groups.
                            ``(x) Health care professionals.
                            ``(xi) State, local, or Tribal governmental 
                        agencies with expertise in the field of 
                        substance use prevention or substance use 
                        disorders (including, if applicable, the State 
                        authority with primary authority for substance 
                        use and misuse).
                            ``(xii) Other organizations involved in 
                        reducing the prevalence of substance use and 
                        misuse or substance use disorders.
                    ``(B) Elected officials.--If feasible, in addition 
                to representatives from the categories listed in 
                subparagraph (A), the coalition shall have an elected 
                official (or a representative of an elected official) 
                from--
                            ``(i) the Federal Government; and
                            ``(ii) the government of the appropriate 
                        State and political subdivision thereof or the 
                        governing body or an Indian tribe (as that term 
                        is defined in section 4(e) of the Indian Self-
                        Determination Act (25 U.S.C. 5304)).
                    ``(C) Representation.--An individual who is a 
                member of the coalition may serve on the coalition as a 
                representative of not more than one category listed 
                under subparagraph (A).
            ``(3) Commitment.--The coalition shall demonstrate, to the 
        satisfaction of the Administrator--
                    ``(A) that the representatives of the coalition 
                have worked together on substance use and misuse 
                reduction initiatives, which, at a minimum, includes 
                initiatives that target drugs described in section 
                1027(6)(A), for a period of not less than 6 months, 
                acting through entities such as task forces, 
                subcommittees, or community boards; and
                    ``(B) substantial participation from volunteer 
                leaders in the community involved (especially in 
                cooperation with individuals involved with youth such 
                as parents, teachers, coaches, youth workers, and 
                members of the clergy).
            ``(4) Mission and strategies.--The coalition shall, with 
        respect to the community involved--
                    ``(A) have as its principal mission the reduction 
                of illegal drug use, which, at a minimum, includes the 
                use of illegal drugs described in section 1027(6)(A), 
                in a comprehensive and long-term manner, with a primary 
                focus on youth in the community;
                    ``(B) describe and document the nature and extent 
                of the substance use and misuse problem, which, at a 
                minimum, includes the use and misuse of drugs described 
                in section 1027(6)(A), in the community;
                    ``(C)(i) provide a description of substance use and 
                misuse prevention and treatment programs and 
                activities, which, at a minimum, includes programs and 
                activities relating to the use and misuse of drugs 
                described in section 1027(6)(A), in existence at the 
                time of the grant application; and
                    ``(ii) identify substance use and misuse programs 
                and service gaps, which, at a minimum, includes 
                programs and gaps relating to the use and misuse of 
                drugs described in section 1027(6)(A), in the 
                community;
                    ``(D) develop a strategic plan to reduce substance 
                use and misuse among youth, which, at a minimum, 
                includes the use and misuse of drugs described in 
                section 1027(6)(A), in a comprehensive and long-term 
                fashion; and
                    ``(E) work to develop a consensus regarding the 
                priorities of the community to combat substance use and 
                misuse among youth, which, at a minimum, includes the 
                use and misuse of drugs described in section 
                1027(6)(A).
            ``(5) Sustainability.--The coalition shall demonstrate that 
        the coalition is an ongoing concern by demonstrating that the 
        coalition--
                    ``(A) is--
                            ``(i)(I) a nonprofit organization; or
                            ``(II) an entity that the Administrator 
                        determines to be appropriate; or
                            ``(ii) part of, or is associated with, an 
                        established legal entity;
                    ``(B) receives financial support (including, in the 
                discretion of the Administrator, in-kind contributions) 
                from non-Federal sources; and
                    ``(C) has a strategy to solicit substantial 
                financial support from non-Federal sources to ensure 
                that the coalition and the programs operated by the 
                coalition are self-sustaining.
            ``(6) Accountability.--The coalition shall--
                    ``(A) establish a system to measure and report 
                outcomes--
                            ``(i) consistent with common indicators and 
                        evaluation protocols established by the 
                        Administrator; and
                            ``(ii) approved by the Administrator;
                    ``(B) conduct--
                            ``(i) for an initial grant under this 
                        subchapter, an initial benchmark survey of drug 
                        use among youth (or use local surveys or 
                        performance measures available or accessible in 
                        the community at the time of the grant 
                        application); and
                            ``(ii) biennial surveys (or incorporate 
                        local surveys in existence at the time of the 
                        evaluation) to measure the progress and 
                        effectiveness of the coalition; and
                    ``(C) provide assurances that the entity conducting 
                an evaluation under this paragraph, or from which the 
                coalition receives information, has experience--
                            ``(i) in gathering data related to 
                        substance use and misuse among youth; or
                            ``(ii) in evaluating the effectiveness of 
                        community anti-drug coalitions.
            ``(7) Additional criteria.--The Director shall not impose 
        any eligibility criteria on new applicants or renewal grantees 
        not provided in this chapter.
    ``(b) Grant Amounts.--
            ``(1) In general.--
                    ``(A) Grants.--
                            ``(i) In general.--Subject to clause (iv), 
                        for a fiscal year, the Administrator may grant 
                        to an eligible coalition under this paragraph, 
                        an amount not to exceed the amount of non-
                        Federal funds raised by the coalition, 
                        including in-kind contributions, for that 
                        fiscal year.
                            ``(ii) Suspension of grants.--If such grant 
                        recipient fails to continue to meet the 
                        criteria specified in subsection (a), the 
                        Administrator may suspend the grant, after 
                        providing written notice to the grant recipient 
                        and an opportunity to appeal.
                            ``(iii) Renewal grants.--Subject to clause 
                        (iv), the Administrator may award a renewal 
                        grant to a grant recipient under this 
                        subparagraph for each fiscal year following the 
                        fiscal year for which an initial grant is 
                        awarded, in an amount not to exceed the amount 
                        of non-Federal funds raised by the coalition, 
                        including in-kind contributions, for that 
                        fiscal year, during the 4-year period following 
                        the period of the initial grant.
                            ``(iv) Limitation.--The amount of a grant 
                        award under this subparagraph may not exceed 
                        $125,000 for a fiscal year.
                    ``(B) Coalition awards.--
                            ``(i) In general.--Except as provided in 
                        clause (ii), the Administrator may, with 
                        respect to a community, make a grant to one 
                        eligible coalition that represents that 
                        community.
                            ``(ii) Exception.--The Administrator may 
                        make a grant to more than one eligible 
                        coalition that represents a community if--
                                    ``(I) the eligible coalitions 
                                demonstrate that the coalitions are 
                                collaborating with one another; and
                                    ``(II) each of the coalitions has 
                                independently met the requirements set 
                                forth in subsection (a).
            ``(2) Rural coalition grants.--
                    ``(A) In general.--
                            ``(i) In general.--In addition to awarding 
                        grants under paragraph (1), to stimulate the 
                        development of coalitions in sparsely populated 
                        and rural areas, the Administrator may award a 
                        grant in accordance with this section to a 
                        coalition that represents a county with a 
                        population that does not exceed 30,000 
                        individuals. In awarding a grant under this 
                        paragraph, the Administrator may waive any 
                        requirement under subsection (a) if the 
                        Administrator considers that waiver to be 
                        appropriate.
                            ``(ii) Matching requirement.--Subject to 
                        subparagraph (C), for a fiscal year, the 
                        Administrator may grant to an eligible 
                        coalition under this paragraph, an amount not 
                        to exceed the amount of non-Federal funds 
                        raised by the coalition, including in-kind 
                        contributions, for that fiscal year.
                            ``(iii) Suspension of grants.--If such 
                        grant recipient fails to continue to meet any 
                        criteria specified in subsection (a) that has 
                        not been waived by the Administrator pursuant 
                        to clause (i), the Administrator may suspend 
                        the grant, after providing written notice to 
                        the grant recipient and an opportunity to 
                        appeal.
                    ``(B) Renewal grants.--The Administrator may award 
                a renewal grant to an eligible coalition that is a 
                grant recipient under this paragraph for each fiscal 
                year following the fiscal year for which an initial 
                grant is awarded, in an amount not to exceed the amount 
                of non-Federal funds raised by the coalition, including 
                in-kind contributions, during the 4-year period 
                following the period of the initial grant.
                    ``(C) Limitations.--
                            ``(i) Amount.--The amount of a grant award 
                        under this paragraph shall not exceed $125,000 
                        for a fiscal year.
                            ``(ii) Awards.--With respect to a county 
                        referred to in subparagraph (A), the 
                        Administrator may award a grant under this 
                        section to not more than one eligible coalition 
                        that represents the county.
            ``(3) Additional grants.--
                    ``(A) In general.--Subject to subparagraph (F), the 
                Administrator may award an additional grant under this 
                paragraph to an eligible coalition awarded a grant 
                under paragraph (1) or (2) for any first fiscal year 
                after the end of the 4-year period following the period 
                of the initial grant under paragraph (1) or (2), as the 
                case may be.
                    ``(B) Scope of grants.--A coalition awarded a grant 
                under paragraph (1) or (2), including a renewal grant 
                under such paragraph, may not be awarded another grant 
                under such paragraph, and is eligible for an additional 
                grant under this section only under this paragraph.
                    ``(C) No priority for applications.--The 
                Administrator may not afford a higher priority in the 
                award of an additional grant under this paragraph than 
                the Administrator would afford the applicant for the 
                grant if the applicant were submitting an application 
                for an initial grant under paragraph (1) or (2) rather 
                than an application for a grant under this paragraph.
                    ``(D) Renewal grants.--Subject to subparagraph (F), 
                the Administrator may award a renewal grant to a grant 
                recipient under this paragraph for each of the fiscal 
                years of the 4-fiscal-year period following the fiscal 
                year for which the initial additional grant under 
                subparagraph (A) is awarded in an amount not to exceed 
                amounts as follows:
                            ``(i) For the first and second fiscal years 
                        of that 4-fiscal-year period, the amount of the 
                        non-Federal funds, including in-kind 
                        contributions, raised by the coalition for the 
                        applicable fiscal year is not less than 125 
                        percent of the amount awarded.
                            ``(ii) For the third and fourth fiscal 
                        years of that 4-fiscal-year period, the amount 
                        of the non-Federal funds, including in-kind 
                        contributions, raised by the coalition for the 
                        applicable fiscal year is not less than 150 
                        percent of the amount awarded.
                    ``(E) Suspension.--If a grant recipient under this 
                paragraph fails to continue to meet the criteria 
                specified in subsection (a), the Administrator may 
                suspend the grant, after providing written notice to 
                the grant recipient and an opportunity to appeal.
                    ``(F) Limitation.--The amount of a grant award 
                under this paragraph may not exceed $125,000 for a 
                fiscal year.
            ``(4) Process for suspension.--A grantee shall not be 
        suspended or terminated under paragraph (1)(A)(ii), 
        (2)(A)(iii), or (3)(E) unless that grantee is afforded a fair, 
        timely, and independent appeal prior to such suspension or 
        termination.
    ``(c) Treatment of Funds for Coalitions Representing Certain 
Organizations.--Funds appropriated for the substance use and misuse 
activities of a coalition that includes a representative of the Bureau 
of Indian Affairs, the Indian Health Service, or a Tribal government 
agency with expertise in the field of substance use prevention may be 
counted as non-Federal funds raised by the coalition for purposes of 
this section.
    ``(d) Priority in Awarding Grants.--In awarding grants under 
subsection (b)(1)(A)(i), priority shall be given to a coalition serving 
economically disadvantaged areas.
``Sec. 1023. Information collection and dissemination with respect to 
              grant recipients
    ``(a) Coalition Information.--
            ``(1) General auditing authority.--For the purpose of audit 
        and examination, the Administrator--
                    ``(A) shall have access to any books, documents, 
                papers, and records that are pertinent to any grant or 
                grant renewal request under this subchapter; and
                    ``(B) may periodically request information from a 
                grant recipient to ensure that the grant recipient 
                meets the applicable criteria under section 1022(a).
            ``(2) Application process.--The Administrator shall issue a 
        request for proposal regarding, with respect to the grants 
        awarded under section 1022, the application process, grant 
        renewal, and suspension or withholding of renewal grants. Each 
        application under this paragraph shall be in writing and shall 
        be subject to review by the Administrator.
            ``(3) Reporting.--The Administrator shall, to the maximum 
        extent practicable and in a manner consistent with applicable 
        law, minimize reporting requirements by a grant recipient and 
        expedite any application for a renewal grant made under this 
        subchapter.
    ``(b) Data Collection and Dissemination.--
            ``(1) In general.--The Administrator may collect data 
        from--
                    ``(A) national substance use and misuse 
                organizations that work with eligible coalitions, 
                community anti-drug coalitions, departments or agencies 
                of the Federal Government, or State or local 
                governments and the governing bodies of Indian Tribes; 
                and
                    ``(B) any other entity or organization that carries 
                out activities that relate to the purposes of the 
                Program.
            ``(2) Activities of administrator.--The Administrator may--
                    ``(A) evaluate the utility of specific initiatives 
                relating to the purposes of the Program;
                    ``(B) conduct an evaluation of the Program; and
                    ``(C) disseminate information described in this 
                subsection to--
                            ``(i) eligible coalitions and other 
                        substance use prevention organizations; and
                            ``(ii) the general public.
            ``(3) Consultation.--The Administrator shall carry out 
        activities under this subsection in consultation with the 
        National Community Antidrug Coalition Institute.
            ``(4) Limitation on use of certain funds for evaluation of 
        program.--Amounts for activities under paragraph (2)(B) may not 
        be derived from amounts under section 1028(a) except for 
        amounts that are available under section 1028(b) for 
        administrative costs.
``Sec. 1024. Technical assistance and training
    ``(a) In General.--
            ``(1) Technical assistance and agreements.--With respect to 
        any grant recipient or other organization, the Administrator 
        may--
                    ``(A) offer technical assistance and training; and
                    ``(B) enter into contracts and cooperative 
                agreements.
            ``(2) Coordination of programs.--The Administrator may 
        facilitate the coordination of programs between a grant 
        recipient and other organizations and entities.
    ``(b) Training.--The Administrator may provide training to any 
representative designated by a grant recipient in--
            ``(1) coalition building;
            ``(2) task force development;
            ``(3) mediation and facilitation, direct service, 
        assessment and evaluation; or
            ``(4) any other activity related to the purposes of the 
        Program.
``Sec. 1025. Supplemental grants for coalition mentoring activities
    ``(a) Authority to Make Grants.--As part of the Program, the 
Director may award an initial grant under this subsection, and renewal 
grants under subsection (f), to any coalition awarded a grant under 
section 1022 that meets the criteria specified in subsection (d) in 
order to fund coalition mentoring activities by such coalition in 
support of the program.
    ``(b) Treatment With Other Grants.--
            ``(1) Supplement.--A grant awarded to a coalition under 
        this section is in addition to any grant awarded to the 
        coalition under section 1022.
            ``(2) Requirement for basic grant.--A coalition may not be 
        awarded a grant under this section for a fiscal year unless the 
        coalition was awarded a grant or renewal grant under section 
        1022(b) for that fiscal year.
    ``(c) Application.--A coalition seeking a grant under this section 
shall submit to the Administrator an application for the grant in such 
form and manner as the Administrator may require.
    ``(d) Criteria.--A coalition meets the criteria specified in this 
subsection if the coalition--
            ``(1) has been in existence for at least 5 years;
            ``(2) has achieved, by or through its own efforts, 
        measurable results in the prevention and treatment of substance 
        use and misuse among youth;
            ``(3) has staff or members willing to serve as mentors for 
        persons seeking to start or expand the activities of other 
        coalitions in the prevention and treatment of substance use and 
        misuse;
            ``(4) has demonstrable support from some members of the 
        community in which the coalition mentoring activities to be 
        supported by the grant under this section are to be carried 
        out; and
            ``(5) submits to the Administrator a detailed plan for the 
        coalition mentoring activities to be supported by the grant 
        under this section.
    ``(e) Use of Grant Funds.--A coalition awarded a grant under this 
section shall use the grant amount for mentoring activities to support 
and encourage the development of new, self-supporting community 
coalitions that are focused on the prevention and treatment of 
substance use and misuse in such new coalitions' communities. The 
mentoring coalition shall encourage such development in accordance with 
the plan submitted by the mentoring coalition under subsection (d)(5).
    ``(f) Renewal Grants.--The Administrator may make a renewal grant 
to any coalition awarded a grant under subsection (a), or a previous 
renewal grant under this subsection, if the coalition, at the time of 
application for such renewal grant--
            ``(1) continues to meet the criteria specified in 
        subsection (d); and
            ``(2) has made demonstrable progress in the development of 
        one or more new, self-supporting community coalitions that are 
        focused on the prevention and treatment of substance use and 
        misuse.
    ``(g) Grant Amounts.--
            ``(1) In general.--Subject to paragraphs (2) and (3), the 
        total amount of grants awarded to a coalition under this 
        section for a fiscal year may not exceed the amount of non-
        Federal funds raised by the coalition, including in-kind 
        contributions, for that fiscal year. Funds appropriated for the 
        substance use and misuse activities of a coalition that 
        includes a representative of the Bureau of Indian Affairs, the 
        Indian Health Service, or a Tribal government agency with 
        expertise in the field of substance use prevention may be 
        counted as non-Federal funds raised by the coalition.
            ``(2) Initial grants.--The amount of the initial grant 
        awarded to a coalition under subsection (a) may not exceed 
        $75,000.
            ``(3) Renewal grants.--The total amount of renewal grants 
        awarded to a coalition under subsection (f) for any fiscal year 
        may not exceed $75,000.
    ``(h) Fiscal Year Limitation on Amount Available for Grants.--The 
total amount available for grants under this section, including renewal 
grants under subsection (f), in any fiscal year may not exceed the 
amount equal to 5 percent of the amount authorized to be appropriated 
by section 1028 for that fiscal year.
    ``(i) Priority in Awarding Initial Grants.--In awarding initial 
grants under this section, priority shall be given to a coalition that 
expressly proposes to provide mentorship to a coalition or aspiring 
coalition serving economically disadvantaged areas.
``Sec. 1026. Authorization for National Community Antidrug Coalition 
              Institute
    ``(a) In General.--The Director shall, using amounts authorized to 
be appropriated by subsection (d), make a competitive grant to provide 
for the continuation of the National Community Anti-drug Coalition 
Institute.
    ``(b) Eligible Organizations.--An organization eligible for the 
grant under subsection (a) is any national nonprofit organization that 
represents, provides technical assistance and training to, and has 
special expertise and broad, national-level experience in community 
antidrug coalitions under this subchapter.
    ``(c) Use of Grant Amount.--The organization that receives the 
grant under subsection (a) shall continue a National Community Anti-
Drug Coalition Institute to--
            ``(1) provide education, training, and technical assistance 
        for coalition leaders and community teams, with emphasis on the 
        development of coalitions serving economically disadvantaged 
        areas;
            ``(2) develop and disseminate evaluation tools, mechanisms, 
        and measures to better assess and document coalition 
        performance measures and outcomes; and
            ``(3) bridge the gap between research and practice by 
        translating knowledge from research into practical information.
    ``(d) Authorization of Appropriations.--The Director shall, using 
amounts authorized to be appropriated by section 1028, make a grant of 
$2 million under subsection (a), for each of the fiscal years 2019 
through 2023.
``Sec. 1027. Definitions
    ``In this subchapter:
            ``(1) Administrator.--The term `Administrator' means the 
        Administrator appointed by the Director under section 1021(c).
            ``(2) Community.--The term `community' shall have the 
        meaning provided that term by the Administrator.
            ``(3) Eligible coalition.--The term `eligible coalition' 
        means a coalition that meets the applicable criteria under 
        section 1022(a).
            ``(4) Grant recipient.--The term `grant recipient' means 
        the recipient of a grant award under section 1022.
            ``(5) Program.--The term `Program' means the program 
        established under section 1021(a).
            ``(6) Substance use and misuse.--The term `substance use 
        and misuse' means--
                    ``(A) the illegal use or misuse of drugs, including 
                substances for which a listing is in effect under any 
                of schedules I through V under section 202 of the 
                Controlled Substances Act (21 U.S.C. 812);
                    ``(B) the misuse of inhalants or over the counter 
                drugs; or
                    ``(C) the use of alcohol, tobacco, or other related 
                product as such use is prohibited by State or local 
                law.
            ``(7) Youth.--The term `youth' shall have the meaning 
        provided that term by the Administrator.
``Sec. 1028. Drug-free communities reauthorization
    ``(a) Authorization of Appropriations.--There are authorized to be 
appropriated to the Office to carry out this subchapter $99 million for 
each of the fiscal years 2019 through 2023.
    ``(b) Administrative Costs.--Not more than 8 percent of the funds 
appropriated for this subchapter may be used by the Office or, in the 
discretion of the Director, an agency delegated to carry out the 
program under section 1021(d) to pay for administrative costs 
associated with carrying out the program.''.
    (d) Technical and Conforming Amendment.--The table of chapters for 
subtitle I of title 31, United States Code, is amended by adding at the 
end the following new item:

``10. Office of National Drug Control.......................    1001''.

SEC. 3. HIGH INTENSITY DRUG TRAFFICKING AREAS PROGRAM.

    (a) Establishment.--
            (1) In general.--There is established in the Office a 
        program to be known as the High Intensity Drug Trafficking 
        Areas Program (in this section referred to as the ``Program'').
            (2) Purpose.--The purpose of the Program is to reduce drug 
        trafficking and drug production in the United States by--
                    (A) facilitating cooperation among Federal, State, 
                local, and Tribal law enforcement agencies to share 
                information and implement coordinated enforcement 
                activities;
                    (B) enhancing law enforcement intelligence sharing 
                among Federal, State, local, and Tribal law enforcement 
                agencies;
                    (C) providing reliable law enforcement intelligence 
                to law enforcement agencies needed to design effective 
                enforcement strategies and operations; and
                    (D) supporting coordinated law enforcement 
                strategies which maximize use of available resources to 
                reduce the supply of illegal drugs in designated areas 
                and in the United States as a whole.
    (b) Designation.--
            (1) In general.--The Director, in consultation with the 
        Attorney General, the Secretary of the Treasury, the Secretary 
        of Homeland Security, the head of each National Drug Control 
        Program Agency, and the Governor of each applicable State, may 
        designate any specified area of the United States as a high 
        intensity drug trafficking area.
            (2) Activities.--After making a designation under paragraph 
        (1) and in order to provide Federal assistance to the area so 
        designated, the Director may--
                    (A) obligate such sums as are appropriated for the 
                Program;
                    (B) direct the temporary reassignment of Federal 
                personnel to such area, subject to the approval of the 
                head of the agency that employs such personnel;
                    (C) take any other action authorized under this 
                section or chapter 10 of title 31, United States Code, 
                as added by section 2(c), to provide increased Federal 
                assistance to those areas; and
                    (D) coordinate activities under this section 
                (specifically administrative, recordkeeping, and funds 
                management activities) with State, local, and Tribal 
                officials.
    (c) Petitions for Designation.--The Director shall establish and 
maintain regulations under which a coalition of interested law 
enforcement agencies from an area may petition for designation as a 
high intensity drug trafficking area (in this section referred to as 
the ``HIDTA''). Such regulations shall provide for a regular review by 
the Director of the petition, including a recommendation regarding the 
merit of the petition to the Director by a panel of qualified, 
independent experts.
    (d) Factors for Consideration.--In considering whether to designate 
an area under this section as a high intensity drug trafficking area, 
the Director shall consider, in addition to such other criteria as the 
Director considers to be appropriate, the extent to which--
            (1) the area is a significant center of illegal drug 
        production, manufacturing, importation, or distribution;
            (2) State, local, and Tribal law enforcement agencies have 
        committed resources to respond to the drug trafficking problem 
        in the area, thereby indicating a determination to respond 
        aggressively to the problem;
            (3) drug-related activities in the area are having a 
        significant harmful impact in the area, and in other areas of 
        the country; and
            (4) a significant increase in allocation of Federal 
        resources is necessary to respond adequately to drug-related 
        activities in the area.
    (e) Organization of High Intensity Drug Trafficking Areas.--
            (1) Executive board and officers.--To be eligible for funds 
        appropriated under this section, each high intensity drug 
        trafficking area shall be governed by an Executive Board. The 
        Executive Board shall designate a chairman, vice chairman, and 
        any other officers to the Executive Board that it determines 
        are necessary.
            (2) Responsibilities.--The Executive Board of a high 
        intensity drug trafficking area shall be responsible for--
                    (A) providing direction and oversight in 
                establishing and achieving the goals of the high 
                intensity drug trafficking area;
                    (B) managing the funds of the high intensity drug 
                trafficking area;
                    (C) reviewing and approving all funding proposals 
                consistent with the overall objective of the high 
                intensity drug trafficking area; and
                    (D) reviewing and approving all reports to the 
                Director on the activities of the high intensity drug 
                trafficking area.
            (3) Board representation.--None of the funds appropriated 
        under this section may be expended for any high intensity drug 
        trafficking area, or for a partnership or region of a high 
        intensity drug trafficking area, if the Executive Board for 
        such area, region, or partnership, does not apportion an equal 
        number of votes between representatives of participating 
        agencies and representatives of participating State, local, and 
        Tribal agencies. Where it is impractical for an equal number of 
        representatives of agencies and State, local, and Tribal 
        agencies to attend a meeting of an Executive Board in person, 
        the Executive Board may use a system of proxy votes or weighted 
        votes to achieve the voting balance required by this paragraph.
            (4) No agency relationship.--The eligibility requirements 
        of this section are intended to ensure the responsible use of 
        Federal funds. Nothing in this section is intended to create an 
        agency relationship between individual high intensity drug 
        trafficking areas and the Federal Government.
    (f) Use of Funds.--The Director shall ensure that not more than 5 
percent of Federal funds appropriated for the Program are expended for 
substance use disorder treatment programs and not more than 5 percent 
of the Federal funds appropriated for the Program are expended for drug 
prevention programs.
    (g) Counterterrorism Activities.--
            (1) Assistance authorized.--The Director may authorize use 
        of resources available for the Program to assist Federal, 
        State, local, and Tribal law enforcement agencies in 
        investigations and activities related to terrorism and 
        prevention of terrorism, especially but not exclusively with 
        respect to such investigations and activities that are also 
        related to drug trafficking.
            (2) Limitation.--The Director shall ensure--
                    (A) that assistance provided under paragraph (1) 
                remains incidental to the purpose of the Program to 
                reduce drug availability and carry out drug-related law 
                enforcement activities; and
                    (B) that significant resources of the Program are 
                not redirected to activities exclusively related to 
                terrorism, except on a temporary basis under 
                extraordinary circumstances, as determined by the 
                Director.
    (h) Role of Drug Enforcement Administration.--The Director, in 
consultation with the Attorney General, shall ensure that a 
representative of the Drug Enforcement Administration is included in 
the Intelligence Support Center for each high intensity drug 
trafficking area.
    (i) Emerging Threat Response Fund.--
            (1) In general.--Subject to the availability of 
        appropriations, the Director may expend up to 10 percent of the 
        amounts appropriated under this section on a discretionary 
        basis, in accordance with the criteria established under 
        paragraph (2)--
                    (A) to respond to any emerging drug trafficking 
                threat in an existing high intensity drug trafficking 
                area;
                    (B) to establish a new high intensity drug 
                trafficking area; or
                    (C) to expand an existing high intensity drug 
                trafficking area.
            (2) Consideration of impact.--In allocating funds under 
        this subsection, the Director shall consider--
                    (A) the impact of activities funded on reducing 
                overall drug traffic in the United States, or 
                minimizing the probability that an emerging drug 
                trafficking threat will spread to other areas of the 
                United States; and
                    (B) such other criteria as the Director considers 
                appropriate.
    (j) Annual HIDTA Program Budget Submissions.--As part of the 
documentation that supports the President's annual budget request for 
the Office, the Director shall submit to Congress a budget 
justification that includes--
            (1) the amount proposed for each HIDTA, conditional upon a 
        review by the Office of the request submitted by such HIDTA and 
        the performance of such HIDTA, with supporting narrative 
        descriptions and rationale for each request;
            (2) a detailed justification that explains--
                    (A) the reasons for the proposed funding level and 
                how such funding level was determined based on a 
                current assessment of the drug trafficking threat in 
                each high intensity drug trafficking area;
                    (B) how such funding will ensure that the goals and 
                objectives of each such area will be achieved; and
                    (C) how such funding supports the National Drug 
                Control Strategy; and
            (3) the amount of HIDTA funds used to investigate and 
        prosecute organizations and individuals trafficking in each 
        major illicit drug, as identified by the Director, in the prior 
        calendar year, and a description of how those funds were used.
    (k) HIDTA Annual Evaluation Report.--As part of each report 
submitted pursuant to section 1006(a) of title 31, United States Code, 
as added by section 2(c), the Director shall include, for each 
designated high intensity drug trafficking area, a report that--
            (1) describes--
                    (A) the specific purposes for the high intensity 
                drug trafficking area; and
                    (B) the specific long-term and short-term goals and 
                objectives for the high intensity drug trafficking 
                area;
            (2) includes an evaluation of the performance of the high 
        intensity drug trafficking area in accomplishing the specific 
        long-term and short-term goals and objectives identified under 
        subparagraph (1)(B);
            (3) assesses the number and operation of all federally 
        funded drug enforcement task forces within such high intensity 
        drug trafficking area;
            (4) describes--
                    (A) each Federal, State, local, and Tribal drug 
                enforcement task force operating in such high intensity 
                drug trafficking area;
                    (B) how such task forces coordinate with each 
                other, with any high intensity drug trafficking area 
                task force, and with investigations receiving funds 
                from the Organized Crime and Drug Enforcement Task 
                Force;
                    (C) what steps, if any, each such task force takes 
                to share information regarding drug trafficking and 
                drug production with other federally funded drug 
                enforcement task forces in the high intensity drug 
                trafficking area;
                    (D) the role of the high intensity drug trafficking 
                area in coordinating the sharing of such information 
                among task forces;
                    (E) the nature and extent of cooperation by each 
                Federal, State, local, and Tribal participant in 
                ensuring that such information is shared among law 
                enforcement agencies and with the high intensity drug 
                trafficking area;
                    (F) the nature and extent to which information 
                sharing and enforcement activities are coordinated with 
                joint terrorism task forces in the high intensity drug 
                trafficking area; and
                    (G) any recommendations for measures needed to 
                ensure that task force resources are utilized 
                efficiently and effectively to reduce the availability 
                of illegal drugs in the high intensity drug trafficking 
                areas; and
            (5) in consultation with the Director of National 
        Intelligence--
                    (A) evaluates existing and planned law enforcement 
                intelligence systems supported by such high intensity 
                drug trafficking area, or utilized by task forces 
                receiving any funding under the Program, including the 
                extent to which such systems ensure access and 
                availability of law enforcement intelligence to 
                Federal, State, local, and Tribal law enforcement 
                agencies within the high intensity drug trafficking 
                area and outside of such area;
                    (B) evaluates the extent to which Federal, State, 
                local, and Tribal law enforcement agencies 
                participating in each high intensity drug trafficking 
                area are sharing law enforcement intelligence 
                information to assess current drug trafficking threats 
                and design appropriate enforcement strategies; and
                    (C) identifies the measures needed to improve 
                effective sharing of information and law enforcement 
                intelligence regarding drug trafficking and drug 
                production among Federal, State, local, and Tribal law 
                enforcement participating in a high intensity drug 
                trafficking area, and between such agencies and similar 
                agencies outside the high intensity drug trafficking 
                area.
    (l) Coordination of Law Enforcement Intelligence Sharing With 
Organized Crime Drug Enforcement Task Force Program.--
            (1) Drug enforcement intelligence sharing.--The Director, 
        in consultation with the Attorney General, shall ensure that 
        any drug enforcement intelligence obtained by the Intelligence 
        Support Center for each high intensity drug trafficking area is 
        shared, on a timely basis, with the drug intelligence fusion 
        center operated by the Organized Crime Drug Enforcement Task 
        Force of the Department of Justice.
            (2) Certification.--Before the Director awards any funds to 
        a high intensity drug trafficking area, the Director shall 
        certify that the law enforcement entities participating in that 
        HIDTA are providing laboratory seizure data to the national 
        clandestine laboratory database at the El Paso Intelligence 
        Center.
    (m) Authorization of Appropriations.--There is authorized to be 
appropriated to the Office to carry out this section $280 million for 
each fiscal years 2019 through 2023.
    (n) Specific Purposes.--
            (1) In general.--The Director shall ensure that, of the 
        amounts appropriated for a fiscal year for the Program, at 
        least 2.5 percent is used in high intensity drug trafficking 
        areas with severe neighborhood safety and illegal drug 
        distribution problems.
            (2) Required uses.--The funds used under paragraph (1) 
        shall be used to ensure the safety of neighborhoods and the 
        protection of communities, including the prevention of the 
        intimidation of witnesses of illegal drug distribution and 
        related activities and the establishment of or support for 
        programs that provide protection or assistance to witnesses in 
        court proceedings.
            (3) Best practice models.--The Director shall work with the 
        HIDTAs to develop and maintain best practice models to assist 
        State, local, and Tribal governments in addressing witness 
        safety, relocation, financial and housing assistance, or any 
        other services related to witness protection or assistance in 
        cases of illegal drug distribution and related activities. The 
        Director shall ensure dissemination of the best practice models 
        to each HIDTA.

SEC. 4. OPIOID CRISIS RESPONSE.

    (a) Emerging Threat Designation.--The Director shall designate 
opioids and opioid analogues as emerging drug threats, in accordance 
with section 1009 of title 31, United States Code, as added by section 
2(c).
    (b) Opioid Response Plan.--
            (1) Issuance.--Not later than 60 days after the date of the 
        enactment of this Act, the Director shall publish, make 
        publicly available, and notify the President and the 
        appropriate congressional committees of, the plan required 
        under section 1009 of title 31, United States Code, as added by 
        section 2(c), to be designated as the ``National Opioid Crisis 
        Response Plan''.
            (2) Contents.--The Director shall ensure the plan 
        establishes measurable goals, including reducing fatal and non-
        fatal overdoses, and includes the following:
                    (A) An initiative to ensure the United States mail 
                is effectively screened to prevent illicit drugs from 
                entering the United States, including--
                            (i) designating the United States Postal 
                        Service as a National Drug Control Program 
                        Agency;
                            (ii) directing the United States Postal 
                        Service and any other related National Drug 
                        Control Program Agency to take any appropriate 
                        actions necessary to reduce the amount of 
                        illicit drugs entering the country; and
                            (iii) developing an international 
                        coordination plan, in consultation with the 
                        National Drug Control Program Agencies and in 
                        accordance with section 1010 of such title 31, 
                        United States Code, as added by section 2(c), 
                        to include efforts to address international 
                        drug control initiatives and strengthen 
                        bilateral and multilateral strategies to reduce 
                        illicit drugs and precursor chemicals from 
                        entering the United States through 
                        international mail or across land borders or 
                        ports of entry.
                    (B) Support for universal adoption of evidence-
                based prescribing guidelines, including--
                            (i) establishing a task force to supplement 
                        existing prescribing guidelines with evidence-
                        based standards and to facilitate, coordinate, 
                        and, as appropriate, conduct research to inform 
                        such guidelines;
                            (ii) encouraging the adoption of evidence-
                        based prescribing guidelines by each relevant 
                        agency, State and local governments, and 
                        private sector organizations;
                            (iii) issuing guidance to National Drug 
                        Control Program Agencies to, as appropriate, 
                        revise regulations to ensure professionals have 
                        effective continuing education requirements; 
                        and
                            (iv) disseminating and encouraging the 
                        adoption of best practices and evidence-based 
                        guidelines for effective prescribing practices.
                    (C) A program to monitor the prescription drug 
                market and illicit drug market for changes in trends 
                relevant to reducing the supply or demand of such 
                drugs.
                    (D) An initiative to facilitate and coordinate 
                Federal, State and local government initiatives, 
                studies, and pilot or demonstration programs designed 
                to evaluate the benefits of drug courts and related 
                programs that reduce substance use prevalence.
                    (E) A program, developed in coordination with the 
                private sector, to--
                            (i) facilitate the development of treatment 
                        and abuse-deterrent products, in accordance 
                        with section 1010(c) of title 31, United States 
                        Code, as added by section 2(c); and
                            (ii) encourage the expansion of medication 
                        disposal programs and technology.
                    (F) Initiatives to--
                            (i) encourage the National Drug Control 
                        Program Agencies and the program established 
                        under section 1010(d) of title 31, United 
                        States Code, as added by section 2(c), to 
                        prioritize the development of sentencing 
                        standards or model codes for trafficking 
                        opioids and opioid analogues; and
                            (ii) to advise States on establishing laws 
                        and policies to address opioid issues based on 
                        the recommendations developed and set forth by 
                        the President's Commission on Combating Drug 
                        Addiction and the Opioid Crisis.
                    (G) A program to identify successful college 
                recovery programs, including sober housing programs 
                that provide a shared living residence free of alcohol 
                or illicit drug use for individuals recovering from 
                drug or alcohol addiction and substance use disorders, 
                on college campuses and disseminate best practices to 
                Colleges and Universities to increase the number and 
                capacity of such programs.
                    (H) Convening working groups, consisting of the 
                appropriate National Drug Control Program Agencies, 
                State, local and Tribal governments, and other 
                appropriate stakeholders, established in accordance 
                with section 1010 of title 31, United States Code, as 
                added by section 2(c)--
                            (i) to support Prescription Drug Monitoring 
                        Programs by--
                                    (I) facilitating the sharing and 
                                interoperability of program data among 
                                States and Federal prescription drug 
                                monitoring programs;
                                    (II) assisting States in increasing 
                                utilization of such programs;
                                    (III) facilitating efforts to 
                                incorporate available overdose and 
                                naloxone deployment data into such 
                                programs;
                                    (IV) evaluating barriers to 
                                integrating program data with 
                                electronic health records; and
                                    (V) offering recommendations to 
                                address identified barriers; and
                            (ii) to develop standards, and encourage 
                        the use of such standards, for the collection 
                        of data necessary to understand and monitor the 
                        opioid crisis, including--
                                    (I) State medical examiner reports 
                                on deaths caused by overdoses and 
                                related statistical data; and
                                    (II) first responder opioid 
                                intoxication incidents.
                    (I) Research initiatives, to be initiated not later 
                than 30 days after the issuance of the plan, to 
                evaluate the uses and barriers to use of and the 
                effects of improving the following programs:
                            (i) Medication Assisted Treatment.
                            (ii) Data collection systems used to 
                        confirm opioid use by individuals who have been 
                        arrested or hospitalized.
                    (J) A requirement for an Advisory Committee on 
                Substance Use Disorder Treatment Standards, to be 
                established not later than 120 days after the issuance 
                of the plan, to promulgate model evidence-based 
                standards for substance use disorder treatment and 
                recovery facilities which--
                            (i) shall be chaired by the Director;
                            (ii) shall include as members of the 
                        advisory committee representatives of the 
                        relevant National Drug Control Program 
                        Agencies;
                            (iii) may include as members of the 
                        advisory committee government regulators, State 
                        representatives, consumer representatives, 
                        substance use disorder treatment providers, 
                        recovery residence owners and operators, and 
                        purchasers of substance use disorder 
                        treatments; and
                            (iv) shall ensure such model standards are 
                        promulgated no later than 2 years after the 
                        date of the issuance of the plan.
    (c) Recommendations.--Not later than 1 year after the date of the 
enactment of this Act, the Director shall submit to the appropriate 
congressional committees a report on the results of the initiatives 
conducted under subsection (b)(2)(I) and may include recommendations 
based on such results.
    (d) Grant Report to Congress.--Not later than 1 year after the date 
of the enactment of this Act, the Director shall submit to the 
appropriate congressional committees an assessment on the feasibility 
of block grants of Federal funding to States.

SEC. 5. EXCEPTIONS AND RULES OF CONSTRUCTION.

    (a) Inapplicability to Certain Programs.--This Act, and the 
amendments made by this Act, shall not apply to the National 
Intelligence Program and the Military Intelligence Program, unless such 
program or an element of such program is designated as a National Drug 
Control Program--
            (1) by the President; or
            (2) jointly by--
                    (A) in the case of the National Intelligence 
                Program, the Director and the Director of National 
                Intelligence; or
                    (B) in the case of the Military Intelligence 
                Program, the Director, the Director of National 
                Intelligence, and the Secretary of Defense.
    (b) Classified Information.--Any contents of any report required 
under this Act, or the amendments made by this Act, that involve 
information properly classified under criteria established by an 
Executive order shall be presented to Congress separately from the rest 
of such report.
    (c) Use of Existing Resources.--To the extent practicable, the 
Director and the head of each agency shall use existing procedures and 
systems to carry out agency requirements under this Act, and the 
amendments made by this Act.

SEC. 6. GAO AUDIT AND REPORTS.

    Not later than 3 and 6 years after the date of the enactment of 
this Act, the Comptroller General shall--
            (1) conduct an audit relating to the programs and 
        operations of--
                    (A) the Office; and
                    (B) certain programs within the Office, including--
                            (i) the High Intensity Drug Trafficking 
                        Areas Program;
                            (ii) the Drug-Free Communities Program; and
                            (iii) the campaign under section 1009(d) of 
                        title 31, as added by section 2(c); and
            (2) submit to the Director and the appropriate 
        congressional committees a report containing an evaluation of 
        and recommendations on the--
                    (A) policies and activities of the programs and 
                operations subject to the audit;
                    (B) economy, efficiency, and effectiveness in the 
                administration of the reviewed programs and operations; 
                and
                    (C) policy or management changes needed to prevent 
                and detect fraud and abuse in such programs and 
                operations.

SEC. 7. REPEALS.

    (a) Repeals to the Law.--The following provisions are repealed:
            (1) The Office of National Drug Control Policy 
        Reauthorization Act of 1998 (Public Law 105-277; 21 U.S.C. 1701 
        et seq.).
            (2) Chapter 2 of the National Narcotics Leadership Act of 
        1988 (Public Law 100-690; 21 U.S.C. 1501 et seq.).
            (3) Section 203 of the Office of National Drug Control 
        Policy Reauthorization Act of 2006 (Public Law 109-469; 21 
        U.S.C. 1708a).
            (4) Section 1105 of the Office of National Drug Control 
        Policy Reauthorization Act of 2006 (Public Law 109-469; 21 
        U.S.C. 1701 note).
            (5) Section 1110 of Office of National Drug Control Policy 
        Reauthorization Act of 2006 (Public Law 109-469; 21 U.S.C. 1705 
        note).
            (6) Section 1110A of the Office of National Drug Control 
        Policy Reauthorization Act of 2006 (Public Law 109-469; 21 
        U.S.C. 1705 note).
            (7) Section 4 of Public Law 107-82 (21 U.S.C. 1521 note).
    (b) Effect on the Code.--The Law Revision Counsel shall ensure that 
the website and any other publication issued after the date of the 
enactment of this Act for the Office of the Law Revision Counsel shows 
that the laws reflected in subchapter II of chapter 20 and chapter 22 
of nonpositive law title 21 of the United States Code have been 
repealed.

SEC. 8. DEFINITIONS.

    In this Act, the terms ``agency'', ``appropriate congressional 
committees'', ``Director'', ``drug'', ``emerging drug threat'', 
``illicit drug use'', ``illicit drugs'', ``National Drug Control 
Program Agencies'', and ``Office'' have the meaning given those terms 
in section 1001 of title 31, United States Code, as added by section 
2(c).

            Passed the House of Representatives June 20, 2018.

            Attest:

                                                                 Clerk.
115th CONGRESS

  2d Session

                               H. R. 5925

_______________________________________________________________________

                                 AN ACT

 To codify provisions relating to the Office of National Drug Control, 
                        and for other purposes.
```